Richard A Scolyer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6697919/publications.pdf Version: 2024-02-01

		997	1190
801	68,520	114	228
papers	citations	h-index	g-index
833	833	833	62540
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	The Immune Landscape of Cancer. Immunity, 2018, 48, 812-830.e14.	14.3	3,706
2	Genomic Classification of Cutaneous Melanoma. Cell, 2015, 161, 1681-1696.	28.9	2,562
3	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell, 2018, 173, 400-416.e11.	28.9	2,277
4	Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell, 2018, 173, 321-337.e10.	28.9	2,111
5	Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell, 2018, 173, 291-304.e6.	28.9	1,718
6	Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell, 2018, 173, 371-385.e18.	28.9	1,670
7	Melanoma staging: Evidenceâ€based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. Ca-A Cancer Journal for Clinicians, 2017, 67, 472-492.	329.8	1,662
8	Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell, 2018, 173, 338-354.e15.	28.9	1,417
9	Whole-genome landscapes of major melanoma subtypes. Nature, 2017, 545, 175-180.	27.8	1,068
10	Prognostic and Clinicopathologic Associations of Oncogenic <i>BRAF</i> in Metastatic Melanoma. Journal of Clinical Oncology, 2011, 29, 1239-1246.	1.6	942
11	Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Reports, 2018, 23, 239-254.e6.	6.4	801
12	Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell, 2018, 33, 676-689.e3.	16.8	750
13	Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncology, The, 2018, 19, 672-681.	10.7	732
14	Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma. Journal of Clinical Oncology, 2012, 30, 2678-2683.	1.6	691
15	Loss of 5-Hydroxymethylcytosine Is an Epigenetic Hallmark of Melanoma. Cell, 2012, 150, 1135-1146.	28.9	688
16	Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. Cell Reports, 2018, 23, 181-193.e7.	6.4	683
17	Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. Cancer Cell, 2018, 34, 211-224.e6.	16.8	623
18	Pathogenic Germline Variants in 10,389 Adult Cancers. Cell, 2018, 173, 355-370.e14.	28.9	620

#	Article	IF	CITATIONS
19	Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Systems, 2018, 6, 271-281.e7.	6.2	605
20	Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma. Clinical Cancer Research, 2012, 18, 1386-1394.	7.0	589
21	Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nature Communications, 2012, 3, 724.	12.8	567
22	Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. Cancer Cell, 2019, 35, 238-255.e6.	16.8	547
23	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Reports, 2018, 23, 313-326.e5.	6.4	523
24	Cutaneous melanoma. Lancet, The, 2005, 365, 687-701.	13.7	511
25	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell, 2018, 33, 690-705.e9.	16.8	478
26	A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. New England Journal of Medicine, 2015, 373, 1618-1626.	27.0	469
27	BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact. Clinical Cancer Research, 2014, 20, 1965-1977.	7.0	447
28	Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treatment Reviews, 2017, 52, 71-81.	7.7	437
29	Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. Cell Reports, 2018, 23, 227-238.e3.	6.4	407
30	Distinguishing Clinicopathologic Features of Patients with V600E and V600K <i>BRAF</i> -Mutant Metastatic Melanoma. Clinical Cancer Research, 2012, 18, 3242-3249.	7.0	405
31	IncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic IncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. Cancer Cell, 2018, 33, 706-720.e9.	16.8	400
32	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell, 2018, 33, 721-735.e8.	16.8	396
33	Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma. Cancer, 2003, 97, 1488-1498.	4.1	372
34	<scp>PD</scp> â€L1 expression in melanoma shows marked heterogeneity within and between patients: implications for antiâ€ <scp>PD</scp> â€1/ <scp>PD</scp> â€ <scp>L</scp> 1 clinical trials. Pigment Cell and Melanoma Research, 2015, 28, 245-253.	3.3	356
35	Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. Clinical Cancer Research, 2020, 26, 487-504.	7.0	355
36	Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncology, The, 2019, 20, 948-960.	10.7	346

#	Article	IF	CITATIONS
37	Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond. Annals of Surgical Oncology, 2018, 25, 2105-2110.	1.5	338
38	Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. Cell Reports, 2018, 23, 282-296.e4.	6.4	333
39	Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. Cell Reports, 2018, 25, 1304-1317.e5.	6.4	329
40	CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-NaÃ⁻ve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment. Clinical Cancer Research, 2018, 24, 3036-3045.	7.0	297
41	Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nature Communications, 2014, 5, 5694.	12.8	295
42	Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma. American Journal of Surgical Pathology, 2013, 37, 61-65.	3.7	289
43	Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma. Clinical Cancer Research, 2018, 24, 1260-1270.	7.0	289
44	Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. Cell Systems, 2018, 6, 282-300.e2.	6.2	284
45	Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget, 2015, 6, 42008-42018.	1.8	278
46	Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell, 2018, 173, 305-320.e10.	28.9	272
47	UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. Cancer Research, 2015, 75, 5228-5234.	0.9	270
48	Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. European Journal of Cancer, 2015, 51, 2792-2799.	2.8	269
49	High response rate to PD-1 blockade in desmoplastic melanomas. Nature, 2018, 553, 347-350.	27.8	269
50	Tissue-resident memory CD8+ T cells promote melanoma–immune equilibrium in skin. Nature, 2019, 565, 366-371.	27.8	266
51	The Impact of In Vivo Reflectance Confocal Microscopy on the Diagnostic Accuracy of Lentigo Maligna and Equivocal Pigmented and Nonpigmented Macules of the Face. Journal of Investigative Dermatology, 2010, 130, 2080-2091.	0.7	261
52	Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncology, The, 2012, 13, 589-597.	10.7	253
53	PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer, 2015, 89, 181-188.	2.0	253
54	Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Annals of Oncology, 2017, 28, 1130-1136.	1.2	253

#	Article	IF	CITATIONS
55	In Vivo Confocal Microscopy for Diagnosis of Melanoma and Basal Cell Carcinoma Using a Two-Step Method: Analysis of 710 Consecutive Clinically Equivocal Cases. Journal of Investigative Dermatology, 2012, 132, 2386-2394.	0.7	252
56	Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy. Clinical Cancer Research, 2019, 25, 1557-1563.	7.0	249
57	The significance of the Wnt pathway in the pathology of human cancers. Pathology, 2004, 36, 120-128.	0.6	246
58	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Reports, 2018, 23, 194-212.e6.	6.4	245
59	Tumours associated with BAP1 mutations. Pathology, 2013, 45, 116-126.	0.6	242
60	Response of <i>BRAF</i> -Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis. Cancer Discovery, 2014, 4, 423-433.	9.4	242
61	The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway. Archives of Pathology and Laboratory Medicine, 2020, 144, 500-522.	2.5	239
62	Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet, The, 2022, 399, 1718-1729.	13.7	236
63	Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies. JAMA Oncology, 2018, 4, 717.	7.1	229
64	A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. Cell, 2018, 173, 386-399.e12.	28.9	228
65	Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nature Genetics, 2015, 47, 1194-1199.	21.4	221
66	Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nature Medicine, 2021, 27, 301-309.	30.7	218
67	Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil. International Journal of Cancer, 2003, 106, 553-558.	5.1	209
68	Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. Immunity, 2017, 47, 789-802.e9.	14.3	207
69	Pan-Cancer Analysis of IncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. Cell Reports, 2018, 23, 297-312.e12.	6.4	205
70	Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nature Communications, 2019, 10, 3163.	12.8	205
71	Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. Cell Reports, 2018, 23, 255-269.e4.	6.4	204
72	Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma. Clinical Cancer Research, 2017, 23, 5024-5033.	7.0	192

#	Article	IF	CITATIONS
73	Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nature Medicine, 2021, 27, 256-263.	30.7	190
74	Overexpression of the Cell Adhesion Molecules DDR1, Claudin 3, and Ep-CAM in Metaplastic Ovarian Epithelium and Ovarian Cancer. Clinical Cancer Research, 2004, 10, 4427-4436.	7.0	189
75	The Prognostic Importance of Tumor Mitotic Rate Confirmed in 1317 Patients With Primary Cutaneous Melanoma and Long Follow-Up. Annals of Surgical Oncology, 2004, 11, 426-433.	1.5	180
76	<i>BRAF</i> mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell and Melanoma Research, 2011, 24, 345-351.	3.3	180
77	Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?. European Journal of Cancer, 2016, 62, 76-85.	2.8	178
78	Programmed death ligand 1 expression in tripleâ€negative breast cancer is associated with tumourâ€infiltrating lymphocytes and improved outcome. Histopathology, 2016, 69, 25-34.	2.9	177
79	Systematic Analysis of Splice-Site-Creating Mutations in Cancer. Cell Reports, 2018, 23, 270-281.e3.	6.4	177
80	Risk Assessment for Atypical Spitzoid Melanocytic Neoplasms Using FISH to Identify Chromosomal Copy Number Aberrations. American Journal of Surgical Pathology, 2013, 37, 676-684.	3.7	175
81	Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncology, The, 2015, 16, 1049-1060.	10.7	173
82	Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Modern Pathology, 2007, 20, 416-426.	5.5	169
83	MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 15840-15845.	7.1	168
84	Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition. Nature Communications, 2020, 11, 1897.	12.8	165
85	Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. British Journal of Dermatology, 2012, 167, 1153-1160.	1.5	163
86	Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1α and Oxidative Phosphorylation in Melanoma. Cancer Research, 2014, 74, 7037-7047.	0.9	161
87	EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1713-1742.	6.4	159
88	Subungual Melanoma. American Journal of Surgical Pathology, 2007, 31, 1902-1912.	3.7	157
89	BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma. Journal of Investigative Dermatology, 2013, 133, 509-517.	0.7	156
90	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncology, The, 2019, 20, e378-e389.	10.7	155

#	Article	IF	CITATIONS
91	Merkel Cell Polyomavirus Status Is Not Associated with Clinical Course of Merkel Cell Carcinoma. Journal of Investigative Dermatology, 2011, 131, 1631-1638.	0.7	153
92	Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. Modern Pathology, 2017, 30, 1666-1676.	5.5	150
93	Interobserver Reproducibility of Histopathologic Prognostic Variables in Primary Cutaneous Melanomas. American Journal of Surgical Pathology, 2003, 27, 1571-1576.	3.7	147
94	Myopericytoma: a unifying term for a spectrum of tumours that show overlapping features with myofibroma. A review of 14 cases. Journal of Clinical Pathology, 2006, 59, 67-73.	2.0	146
95	Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 10995-11000.	7.1	146
96	Histomorphologic Assessment and Interobserver Diagnostic Reproducibility of Atypical Spitzoid Melanocytic Neoplasms With Long-term Follow-up. American Journal of Surgical Pathology, 2014, 38, 934-940.	3.7	142
97	Activation of CCR9/CCL25 in Cutaneous Melanoma Mediates Preferential Metastasis to the Small Intestine. Clinical Cancer Research, 2008, 14, 638-645.	7.0	141
98	Blue Nevi and Related Lesions. Advances in Anatomic Pathology, 2009, 16, 365-382.	4.3	141
99	A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition. Cancer Discovery, 2014, 4, 69-79.	9.4	141
100	Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. Nature Genetics, 2020, 52, 494-504.	21.4	138
101	Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. Molecular Oncology, 2011, 5, 124-136.	4.6	135
102	Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Annals of Oncology, 2018, 29, 1861-1868.	1.2	135
103	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily. Cell Systems, 2018, 7, 422-437.e7.	6.2	134
104	Desmoplastic neurotropic melanoma. Cancer, 2008, 113, 2770-2778.	4.1	131
105	In-transit Melanoma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy. Annals of Surgical Oncology, 2015, 22, 475-481.	1.5	131
106	Genetic and morphologic features for melanoma classification. Pigment Cell and Melanoma Research, 2010, 23, 763-770.	3.3	130
107	The prognostic significance of sentinel node tumour burden in melanoma patients: An international, multicenter study of 1539 sentinel node-positive melanoma patients. European Journal of Cancer, 2014, 50, 111-120.	2.8	127
108	MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy. Cancer Research, 2017, 77, 4697-4709.	0.9	126

#	Article	IF	CITATIONS
109	Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. Lancet Oncology, The, 2019, 20, 961-971.	10.7	126
110	Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. Pathology, 2021, 53, 141-156.	0.6	126
111	Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant PleuralÂMesothelioma. Journal of Thoracic Oncology, 2017, 12, 1421-1433.	1.1	121
112	Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nature Medicine, 2022, 28, 1178-1188.	30.7	121
113	PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients. Clinical Cancer Research, 2015, 21, 3140-3148.	7.0	120
114	Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. Cell Reports, 2018, 23, 172-180.e3.	6.4	119
115	Micromorphometric Features of Positive Sentinel Lymph Nodes Predict Involvement of Nonsentinel Nodes in Patients With Melanoma. American Journal of Clinical Pathology, 2004, 122, 532-539.	0.7	117
116	Sentinel Lymph Node Biopsy in Histologically Ambiguous Melanocytic Tumors With Spitzoid Features (So-Called Atypical Spitzoid Tumors). Annals of Surgical Oncology, 2008, 15, 302-309.	1.5	116
117	<i>BRAF/NRAS</i> Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage. Clinical Cancer Research, 2013, 19, 4589-4598.	7.0	115
118	Improving Management and Patient Care in Lentigo Maligna by Mapping With In Vivo Confocal Microscopy. JAMA Dermatology, 2013, 149, 692.	4.1	114
119	Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. Oncolmmunology, 2016, 5, e1238557.	4.6	113
120	Spitz naevus versus spitzoid melanoma: when and how can they be distinguished?. Pathology, 2002, 34, 6-12.	0.6	112
121	Non-Sentinel Node Risk Score (N-SNORE): A Scoring System for Accurately Stratifying Risk of Non-Sentinel Node Positivity in Patients With Cutaneous Melanoma With Positive Sentinel Lymph Nodes. Journal of Clinical Oncology, 2010, 28, 4441-4449.	1.6	111
122	Pigmented Epithelioid Melanocytoma: Favorable Outcome After 5-year Follow-up. American Journal of Surgical Pathology, 2009, 33, 1778-1782.	3.7	110
123	Outcome in 846 Cutaneous Melanoma Patients From a Single Center After a Negative Sentinel Node Biopsy. Annals of Surgical Oncology, 2005, 12, 429-439.	1.5	109
124	The role of cell cycle regulatory proteins in the pathogenesis of melanoma. Pathology, 2006, 38, 287-301.	0.6	109
125	Prognostic factors in cutaneous desmoplastic melanoma. Cancer, 2010, 116, 4130-4138.	4.1	109
126	Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nature Communications, 2017, 8, 607.	12.8	109

#	Article	IF	CITATIONS
127	Correlation Between Preoperative Lymphoscintigraphy and Metastatic Nodal Disease Sites in 362 Patients With Cutaneous Melanomas of the Head and Neck. Annals of Surgery, 2004, 239, 544-552.	4.2	106
128	Data Set for Pathology Reporting of Cutaneous Invasive Melanoma. American Journal of Surgical Pathology, 2013, 37, 1797-1814.	3.7	106
129	Sentinel Lymph Node Biopsy in Patients With Thin Primary Cutaneous Melanoma. Annals of Surgery, 2012, 255, 128-133.	4.2	103
130	Dermoscopic Evaluation of Nodular Melanoma. JAMA Dermatology, 2013, 149, 699.	4.1	103
131	Pathologic Review of Negative Sentinel Lymph Nodes in Melanoma Patients With Regional Recurrence. American Journal of Surgical Pathology, 2003, 27, 1197-1202.	3.7	102
132	A distinct molecular profile associated with mucinous epithelial ovarian cancer. British Journal of Cancer, 2006, 94, 904-913.	6.4	102
133	Pathologic examination of sentinel lymph nodes from melanoma patients. Seminars in Diagnostic Pathology, 2008, 25, 100-111.	1.5	102
134	Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. Nature Communications, 2020, 11, 5259.	12.8	102
135	Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma. Nature Cancer, 2021, 2, 693-708.	13.2	102
136	Merkel Cell Carcinoma: Assessing the Effect of Wide Local Excision, Lymph Node Dissection, and Radiotherapy on Recurrence and Survival in Early-Stage Disease—Results From a Review of 82 Consecutive Cases Diagnosed Between 1992 and 2004. Annals of Surgical Oncology, 2007, 14, 1943-1952.	1.5	101
137	Cutaneous melanoma in the era of molecular profiling. Lancet, The, 2009, 374, 362-365.	13.7	100
138	Ultrasound Examination of Sentinel Nodes in the Initial Assessment of Patients With Primary Cutaneous Melanoma. Annals of Surgical Oncology, 2005, 12, 18-23.	1.5	99
139	Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3704-e3713.	3.6	98
140	A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC) Journal of Clinical Oncology, 2017, 35, 9508-9508.	1.6	98
141	The expression of key cell cycle markers and presence of human papillomavirus in squamous cell carcinoma of the tonsil. Head and Neck, 2004, 26, 1-9.	2.0	96
142	Outcomes of Atypical Spitz Tumors With Chromosomal Copy Number Aberrations and Conventional Melanomas in Children. American Journal of Surgical Pathology, 2013, 37, 1387-1394.	3.7	96
143	Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. Human Molecular Genetics, 2014, 23, 226-238.	2.9	96
144	Management of Merkel Cell Carcinoma: The Roles of Lymphoscintigraphy, Sentinel Lymph Node Biopsy and Adjuvant Radiotherapy. Annals of Surgical Oncology, 2008, 15, 2509-2518.	1.5	95

#	Article	IF	CITATIONS
145	Atypical Spitzoid Melanocytic Tumors With Positive Sentinel Lymph Nodes in Children and Teenagers, and Comparison With Histologically Unambiguous and Lethal Melanomas. American Journal of Surgical Pathology, 2009, 33, 1386-1395.	3.7	95
146	Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. British Journal of Cancer, 2014, 111, 292-299.	6.4	93
147	Fibroblast Growth Factor 23: A New Clinical Marker for Oncogenic Osteomalacia. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4088-4094.	3.6	92
148	Phyllodes tumours of the breast: A clinicopathological analysis of 65 cases from a single institution. Breast, 2009, 18, 165-170.	2.2	92
149	Diagnosis of cutaneous melanocytic tumours by four-colour fluorescence in situ hybridisation. Pathology, 2009, 41, 383-387.	0.6	92
150	Targeted High-Resolution Ultrasound Is Not an Effective Substitute for Sentinel Lymph Node Biopsy in Patients With Primary Cutaneous Melanoma. Journal of Clinical Oncology, 2009, 27, 5614-5619.	1.6	91
151	Expression of glucoseâ€regulated stress protein GRP78 is related to progression of melanoma. Histopathology, 2009, 54, 462-470.	2.9	91
152	PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma. Clinical Cancer Research, 2016, 22, 3915-3923.	7.0	91
153	Desmoplastic melanoma: a diagnostic trap for the unwary. Pathology, 2004, 36, 445-451.	0.6	90
154	Recurrent inactivating RASA2 mutations in melanoma. Nature Genetics, 2015, 47, 1408-1410.	21.4	90
155	A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients. British Journal of Dermatology, 2016, 175, 1073-1075.	1.5	88
156	Surgery for melanoma metastases of the gastrointestinal tract: Indications and results. European Journal of Surgical Oncology, 2009, 35, 313-319.	1.0	87
157	Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER). Lancet, The, 2013, 381, 1835-1843.	13.7	87
158	State of the Art, Nomenclature, and Points of Consensus and Controversy Concerning Benign Melanocytic Lesions: Outcome of an International Workshop. Advances in Anatomic Pathology, 2010, 17, 73-90.	4.3	86
159	The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis. EBioMedicine, 2015, 2, 671-680.	6.1	86
160	Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours. Nature Communications, 2020, 11, 2408.	12.8	86
161	SOX2 contributes to melanoma cell invasion. Laboratory Investigation, 2012, 92, 362-370.	3.7	85
162	Checkpoint Inhibitor–Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5499-5506.	3.6	85

#	Article	IF	CITATIONS
163	Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram. Journal of Clinical Oncology, 2020, 38, 2719-2727.	1.6	84
164	Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. Cell Reports, 2018, 23, 213-226.e3.	6.4	83
165	The advantage of using a synoptic pathology report format for cutaneous melanoma. Histopathology, 2008, 52, 130-138.	2.9	82
166	Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic Melanoma. Journal of Investigative Dermatology, 2016, 136, 245-254.	0.7	82
167	Title is missing!. , 2017, , .		82
168	A recurrent germline <i><scp>BAP1</scp></i> mutation and extension of the <i><scp>BAP1</scp></i> tumor predisposition spectrum to include basal cell carcinoma. Clinical Genetics, 2015, 88, 267-272.	2.0	81
169	SF3B1 and BAP1 mutations in blue nevus-like melanoma. Modern Pathology, 2017, 30, 928-939.	5.5	81
170	Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis. Cancer Research, 2017, 77, 4684-4696.	0.9	80
171	SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling. Nature Communications, 2018, 9, 3440.	12.8	80
172	Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitor–Resistant Cutaneous Melanomas. Journal of Investigative Dermatology, 2015, 135, 532-541.	0.7	79
173	Epigenetic profiling for the molecular classification of metastatic brain tumors. Nature Communications, 2018, 9, 4627.	12.8	79
174	CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function. Cancer Immunology Research, 2019, 7, 559-571.	3.4	79
175	CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ TÂCells. Immunity, 2020, 53, 805-823.e15.	14.3	79
176	Intratumoral Molecular Heterogeneity in a <i>BRAF</i> -Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine. Molecular Cancer Therapeutics, 2012, 11, 2704-2708.	4.1	78
177	Genetic and clinico-pathologic analysis of metastatic uveal melanoma. Modern Pathology, 2014, 27, 175-183.	5.5	78
178	Tumor-Infiltrating Lymphocytes and Their Significance in Melanoma Prognosis. Methods in Molecular Biology, 2014, 1102, 287-324.	0.9	78
179	Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial. Journal of Clinical Oncology, 2019, 37, 3132-3141.	1.6	78
180	Hormonal Receptors Expression in Epithelial Cells of Mammary Phyllodes Tumors Correlates With Pathologic Grade of the Tumor. American Journal of Clinical Pathology, 2002, 118, 522-526.	0.7	77

#	Article	IF	CITATIONS
181	Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients. Annals of Oncology, 2019, 30, 815-822.	1.2	77
182	Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. Modern Pathology, 2015, 28, 1535-1544.	5.5	76
183	Interobserver reproducibility of histologic parameters of melanoma deposits in sentinel lymph nodes. Cancer, 2009, 115, 5026-5037.	4.1	75
184	PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors. Clinical Cancer Research, 2017, 23, 6054-6061.	7.0	75
185	Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma. Journal of Clinical Pathology, 2005, 58, 1163-1169.	2.0	74
186	Melanoma of the Vulva and Vagina: Principles of Staging and Their Relevance to Management Based on a Clinicopathologic Analysis of 85 Cases. Annals of Surgical Oncology, 2015, 22, 1959-1966.	1.5	73
187	Diagnosis of Metastatic Melanoma by Fine-Needle Biopsy. American Journal of Clinical Pathology, 2007, 127, 385-397.	0.7	72
188	Radiotherapy for lentigo maligna: a literature review and recommendations for treatment. British Journal of Dermatology, 2014, 170, 52-58.	1.5	72
189	RAB27A promotes melanoma cell invasion and metastasis <i>via</i> regulation of proâ€invasive exosomes. International Journal of Cancer, 2019, 144, 3070-3085.	5.1	72
190	Sentinel Node Biopsy Provides More Accurate Staging Than Elective Lymph Node Dissection in Patients With Cutaneous Melanoma. Annals of Surgical Oncology, 2004, 11, 829-836.	1.5	71
191	Combined naevus: a benign lesion frequently misdiagnosed both clinically and pathologically as melanoma. Pathology, 2004, 36, 419-427.	0.6	71
192	Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor–related apoptosis-inducing ligand. Human Pathology, 2006, 37, 1286-1294.	2.0	71
193	Increased p53 Protein Expression in Malignant Mammary Phyllodes Tumors. Modern Pathology, 2002, 15, 734-740.	5.5	70
194	Transforming growth factor-l²1 immobilises dendritic cells within skin tumours and facilitates tumour escape from the immune system. Cancer Immunology, Immunotherapy, 2005, 54, 898-906.	4.2	70
195	Clinical activity of the <scp>MEK</scp> inhibitor trametinib in metastatic melanoma containing <i><scp>BRAF</scp></i> kinase fusion. Pigment Cell and Melanoma Research, 2015, 28, 607-610.	3.3	70
196	Increased c-kit (CD117) expression in malignant mammary phyllodes tumors. Modern Pathology, 2004, 17, 827-831.	5.5	69
197	Angiotropism is an Independent Predictor of Local Recurrence and In-transit Metastasis in Primary Cutaneous Melanoma. American Journal of Surgical Pathology, 2008, 32, 1396-1403.	3.7	69
198	Dynamics of Chemokine, Cytokine, and Growth Factor Serum Levels in BRAF-Mutant Melanoma Patients during BRAF Inhibitor Treatment. Journal of Immunology, 2014, 192, 2505-2513.	0.8	69

#	Article	IF	CITATIONS
199	Long-Term Survival of Patients with Thin (T1) Cutaneous Melanomas: A Breslow Thickness Cut Point of 0.8Amm Separates Higher-Risk and Lower-Risk Tumors. Annals of Surgical Oncology, 2018, 25, 894-902.	1.5	69
200	Sentinel Lymph Node Biopsy in Pediatric and Adolescent Cutaneous Melanoma Patients. Annals of Surgical Oncology, 2010, 17, 138-143.	1.5	68
201	Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins. Modern Pathology, 2010, 23, 45-53.	5.5	68
202	A Sentinel Node Biopsy Does Not Increase the Incidence of In-Transit Metastasis in Patients With Primary Cutaneous Melanoma. Annals of Surgical Oncology, 2005, 12, 597-608.	1.5	67
203	Long-Term Protective Effect of Mature DC-LAMP+ Dendritic Cell Accumulation in Sentinel Lymph Nodes Containing Micrometastatic Melanoma. Clinical Cancer Research, 2007, 13, 3825-3830.	7.0	67
204	False Negative Sentinel Lymph Node Biopsies in Melanoma May Result From Deficiencies in Nuclear Medicine, Surgery, or Pathology. Annals of Surgery, 2008, 247, 1003-1010.	4.2	67
205	PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma. Nature Communications, 2013, 4, 1508.	12.8	67
206	Determination of prognosis in metastatic melanoma through integration of clinicoâ€pathologic, mutation, mRNA, microRNA, and protein information. International Journal of Cancer, 2015, 136, 863-874.	5.1	67
207	Soâ€called "malignant blue nevusâ€. Cancer, 2009, 115, 2949-2955.	4.1	66
208	Intrapatient Homogeneity of BRAFV600E Expression in Melanoma. American Journal of Surgical Pathology, 2014, 38, 377-382.	3.7	66
209	Stromal expression of vascular endothelial growth factor correlates with tumor grade and microvessel density in mammary phyllodes tumors: A multicenter study of 185 cases. Human Pathology, 2004, 35, 1053-1057.	2.0	65
210	DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations. Neuro-Oncology, 2014, 16, 1499-1509.	1.2	65
211	Genetic Alterations and Personalized Medicine in Melanoma: Progress and Future Prospects. Journal of the National Cancer Institute, 2014, 106, djt435-djt435.	6.3	64
212	Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. Cancer Cell, 2022, 40, 88-102.e7.	16.8	64
213	RIP1 Kinase Is an Oncogenic Driver in Melanoma. Cancer Research, 2015, 75, 1736-1748.	0.9	63
214	LC/MS-Based Quantitative Proteomic Analysis of Paraffin-Embedded Archival Melanomas Reveals Potential Proteomic Biomarkers Associated with Metastasis. PLoS ONE, 2009, 4, e4430.	2.5	62
215	Functional RET G691S polymorphism in cutaneous malignant melanoma. Oncogene, 2009, 28, 3058-3068.	5.9	62
216	Prognostic Importance of the Extent of Ulceration in Patients With Clinically Localized Cutaneous Melanoma. Annals of Surgery, 2012, 255, 1165-1170.	4.2	62

#	Article	IF	CITATIONS
217	Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients. Oncolmmunology, 2020, 9, 1659093.	4.6	62
218	Stromal CD10 expression in mammary fibroadenomas and phyllodes tumours. Journal of Clinical Pathology, 2005, 58, 185-189.	2.0	61
219	Proposed Quality Standards for Regional Lymph Node Dissections in Patients With Melanoma. Annals of Surgery, 2009, 249, 473-480.	4.2	61
220	Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients. Oncolmmunology, 2019, 8, e1537581.	4.6	61
221	Melanoma pathology reporting and staging. Modern Pathology, 2020, 33, 15-24.	5.5	61
222	Counting mitoses: SI(ze) matters!. Modern Pathology, 2021, 34, 1651-1657.	5.5	61
223	Nevus/Melanocytoma/Melanoma: An Emerging Paradigm for Classification of Melanocytic Neoplasms?. Archives of Pathology and Laboratory Medicine, 2011, 135, 300-306.	2.5	61
224	IGFBP7 Is Not Required for B-RAF-Induced Melanocyte Senescence. Cell, 2010, 141, 717-727.	28.9	60
225	Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor. Oncogene, 2014, 33, 1158-1166.	5.9	60
226	Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients. Clinical Cancer Research, 2015, 21, 98-105.	7.0	60
227	A highly recurrent RPS27 5'UTR mutation in melanoma. Oncotarget, 2014, 5, 2912-2917.	1.8	60
228	Increasing Tumor Thickness is Associated with Recurrence and Poorer Survival in Patients with Merkel Cell Carcinoma. Annals of Surgical Oncology, 2012, 19, 3325-3334.	1.5	59
229	MicroRNA and mRNA expression profiling in metastatic melanoma reveal associations with <i>BRAF</i> mutation and patient prognosis. Pigment Cell and Melanoma Research, 2015, 28, 254-266.	3.3	59
230	Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype. Pathology, 2016, 48, 574-580.	0.6	59
231	KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncology, 2020, 16, 4429-4438.	2.4	59
232	Prognostic Gene Expression Profiling in Cutaneous Melanoma. JAMA Dermatology, 2020, 156, 1004.	4.1	59
233	Histopathologic Excision Margin Affects Local Recurrence Rate. Annals of Surgery, 2005, 241, 326-333.	4.2	57
234	Increased epidermal growth factor receptor (EGFR) expression in malignant mammary phyllodes tumors. Breast Cancer Research and Treatment, 2009, 114, 441-448.	2.5	57

#	Article	IF	CITATIONS
235	Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K <i>BRAF</i> -Mutant Melanoma. Clinical Cancer Research, 2019, 25, 1272-1279.	7.0	57
236	The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro. British Journal of Cancer, 2008, 98, 1085-1093.	6.4	56
237	The Importance of Adequate Primary Tumor Excision Margins and Sentinel Node Biopsy in Achieving Optimal Locoregional Control for Patients With Thick Primary Melanomas. Annals of Surgery, 2013, 258, 152-157.	4.2	56
238	Activating cysteinyl leukotriene receptor 2 (CYSLTR2) mutations in blue nevi. Modern Pathology, 2017, 30, 350-356.	5.5	56
239	The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a. Molecular Cancer, 2009, 8, 4.	19.2	55
240	BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma. British Journal of Cancer, 2013, 108, 924-931.	6.4	55
241	AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma. Cell Death and Disease, 2013, 4, e914-e914.	6.3	55
242	Surveillance for treatment failure of lentigo maligna with dermoscopy andin vivoconfocal microscopy: new descriptors. British Journal of Dermatology, 2014, 170, 1305-1312.	1.5	55
243	Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system. Journal of Neuro-Oncology, 2016, 127, 435-444.	2.9	55
244	Molecular Genomic Profiling of MelanocyticÂNevi. Journal of Investigative Dermatology, 2019, 139, 1762-1768.	0.7	55
245	Pathology of melanocytic lesions: New, controversial, and clinically important issues. Journal of Surgical Oncology, 2004, 86, 200-211.	1.7	54
246	Pharmacologically Antagonizing the CXCR4-CXCL12 Chemokine Pathway with AMD3100 Inhibits Sunlight-Induced Skin Cancer. Journal of Investigative Dermatology, 2014, 134, 1091-1100.	0.7	54
247	Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility. International Journal of Cancer, 2019, 144, 1049-1060.	5.1	54
248	Surgical biopsy with intra-operative frozen section. Journal of Bone and Joint Surgery: British Volume, 2006, 88-B, 1207-1211.	3.4	53
249	False-negative sentinel node biopsy because of obstruction of lymphatics by metastatic melanoma: the value of ultrasound in conjunction with preoperative lymphoscintigraphy. Melanoma Research, 2009, 19, 94-99.	1.2	53
250	Dermoscopy and <i>in vivo</i> confocal microscopy are complementary techniques for diagnosis of difficult amelanotic and light-coloured skin lesions. British Journal of Dermatology, 2016, 175, 1311-1319.	1.5	53
251	Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma. Clinical Cancer Research, 2020, 26, 3671-3681.	7.0	53
252	Pigmented Epithelioid Melanocytoma. American Journal of Surgical Pathology, 2004, 28, 1114-1115.	3.7	52

#	Article	IF	CITATIONS
253	Review and Cross-Validation of Gene Expression Signatures and Melanoma Prognosis. Journal of Investigative Dermatology, 2012, 132, 274-283.	0.7	52
254	Elemental bio-imaging of melanoma in lymph node biopsies. Analyst, The, 2009, 134, 450-453.	3.5	51
255	Absence of Distinguishing Senescence Traits in Human Melanocytic Nevi. Journal of Investigative Dermatology, 2012, 132, 2226-2234.	0.7	50
256	Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors. Clinical Cancer Research, 2020, 26, 4064-4071.	7.0	50
257	Desmoplastic Melanoma: A Heterogeneous Entity in Which Subclassification as ?Pure? or ?Mixed? May Have Important Prognostic Significance. Annals of Surgical Oncology, 2005, 12, 197-199.	1.5	49
258	Cancer–testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate. European Journal of Cancer, 2011, 47, 460-469.	2.8	49
259	Isolated Limb Infusion for Advanced Soft Tissue Sarcoma of the Extremity. Annals of Surgical Oncology, 2008, 15, 2749-2756.	1.5	48
260	The detection and significance of melanoma micrometastases in sentinel nodes. Surgical Oncology, 2008, 17, 165-174.	1.6	48
261	Melanomas of unknown primary have a mutation profile consistent with cutaneous sunâ€exposed melanoma. Pigment Cell and Melanoma Research, 2013, 26, 852-860.	3.3	48
262	Accuracy of optical coherence tomography for the diagnosis of superficial basal cell carcinoma: a prospective, consecutive, cohort study of 168 cases. British Journal of Dermatology, 2016, 175, 1290-1300.	1.5	48
263	Increased expression of apoptotic markers in melanoma. Melanoma Research, 2003, 13, 137-145.	1.2	47
264	Spitz naevus: diagnostic problems and their management implications. Pathology, 2004, 36, 452-457.	0.6	47
265	The Complex Relationships Between Sentinel Node Positivity, Patient Age, and Primary Tumor Desmoplasia: Analysis of 2303 Melanoma Patients Treated at a Single Center. Annals of Surgical Oncology, 2008, 15, 630-637.	1.5	47
266	Histologically Ambiguous ("Borderlineâ€) Primary Cutaneous Melanocytic Tumors: Approaches to Patient Management Including the Roles of Molecular Testing and Sentinel Lymph Node Biopsy. Archives of Pathology and Laboratory Medicine, 2010, 134, 1770-1777.	2.5	47
267	Loss of 5-hydroxymethylcytosine correlates with increasing morphologic dysplasia in melanocytic tumors. Modern Pathology, 2014, 27, 936-944.	5.5	46
268	Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling. Nature Communications, 2021, 12, 1434.	12.8	46
269	Interobserver Variation in the Histopathologic Reporting of Key Prognostic Parameters, Particularly Clark Level, Affects Pathologic Staging of Primary Cutaneous Melanoma. Annals of Surgery, 2009, 249, 641-647.	4.2	45
270	Clinicopathologic Features of Incident and Subsequent Tumors in Patients with Multiple Primary Cutaneous Melanomas. Annals of Surgical Oncology, 2012, 19, 1024-1033.	1.5	45

#	Article	IF	CITATIONS
271	A High-Throughput Panel for Identifying Clinically Relevant Mutation Profiles in Melanoma. Molecular Cancer Therapeutics, 2012, 11, 888-897.	4.1	45
272	Sentinel Lymph Nodes Containing Very Small (<0.1Âmm) Deposits of Metastatic Melanoma Cannot Be Safely Regarded as Tumor-Negative. Annals of Surgical Oncology, 2012, 19, 1089-1099.	1.5	45
273	Isolated melanoma in the lung where there is no known primary site: metastatic disease or primary lung tumour?. Melanoma Research, 2005, 15, 531-537.	1.2	44
274	Pravastatin-induced lichenoid drug eruption. Australasian Journal of Dermatology, 2006, 47, 57-59.	0.7	44
275	Oncogenic B-RAFV600E Signaling Induces the T-Box3 Transcriptional Repressor to Repress E-Cadherin and Enhance Melanoma Cell Invasion. Journal of Investigative Dermatology, 2013, 133, 1269-1277.	0.7	44
276	Critical Assessment of Clinical Prognostic Tools in Melanoma. Annals of Surgical Oncology, 2016, 23, 2753-2761.	1.5	44
277	PD-L1 expression in tonsillar cancer is associated with human papillomavirus positivity and improved survival: implications for anti-PD1 clinical trials. Oncotarget, 2016, 7, 77010-77020.	1.8	44
278	Anatomic position determines oncogenic specificity in melanoma. Nature, 2022, 604, 354-361.	27.8	44
279	Can phyllodes tumours of the breast be distinguished from fibroadenomas using fine needle aspiration cytology?. Pathology, 2001, 33, 437-443.	0.6	43
280	Differential gene expression profiling of primary cutaneous melanoma and sentinel lymph node metastases. Modern Pathology, 2012, 25, 828-837.	5.5	43
281	Plasma cells in primary melanoma. Prognostic significance and possible role of IgA. Modern Pathology, 2016, 29, 347-358.	5.5	43
282	The Association Between Excision Margins and Local Recurrence in 11,290 Thin (T1) Primary Cutaneous Melanomas: A Case–Control Study. Annals of Surgical Oncology, 2016, 23, 1082-1089.	1.5	43
283	Skp2-Mediated Stabilization of MTH1 Promotes Survival of Melanoma Cells upon Oxidative Stress. Cancer Research, 2017, 77, 6226-6239.	0.9	43
284	Significant association of PD-L1 expression with human papillomavirus positivity and its prognostic impact in oropharyngeal cancer. Oral Oncology, 2019, 92, 33-39.	1.5	43
285	Clinical Models to Define Response and Survival With Anti–PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. Journal of Clinical Oncology, 2022, 40, 1068-1080.	1.6	43
286	Angiotropism is an independent predictor of microscopic satellites in primary cutaneous melanoma. Histopathology, 2012, 61, 889-898.	2.9	42
287	Margins of excision and prognostic factors for cutaneous eyelid melanomas. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2013, 66, 1066-1073.	1.0	42
288	Reduced expression of p16 and p27 is correlated with tumour progression in cutaneous melanoma. Pathology, 2007, 39, 551-557.	0.6	41

#	Article	IF	CITATIONS
289	Primary cutaneous Ewing sarcoma/primitive neuroectodermal tumour: a clinicopathological analysis of seven cases highlighting diagnostic pitfalls and the role of FISH testing in diagnosis. Journal of Clinical Pathology, 2009, 62, 915-919.	2.0	41
290	Quality of histopathological reporting on melanoma and influence of use of a synoptic template. Histopathology, 2010, 56, 768-774.	2.9	41
291	Primary and Metastatic Cutaneous Melanomas Express ALK Through Alternative Transcriptional Initiation. American Journal of Surgical Pathology, 2016, 40, 786-795.	3.7	41
292	Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy. Clinical Cancer Research, 2020, 26, 5926-5933.	7.0	41
293	Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): Randomized phase 2 study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets) Journal of Clinical Oncology, 2021, 39, 9508-9508.	1.6	41
294	Reduced p16 and Increased Cyclin D1 and pRb Expression Are Correlated With Progression in Cutaneous Melanocytic Tumors. International Journal of Surgical Pathology, 2009, 17, 361-367.	0.8	40
295	The emerging important role of microRNAs in the pathogenesis, diagnosis and treatment of human cancers. Pathology, 2011, 43, 657-671.	0.6	40
296	Clinicopathologic features associated with efficacy and longâ€ŧerm survival in metastatic melanoma patients treated with <scp>BRAF</scp> or combined <scp>BRAF</scp> and MEK inhibitors. Cancer, 2015, 121, 3826-3835.	4.1	40
297	Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas. Laboratory Investigation, 2017, 97, 130-145.	3.7	40
298	Conditional Survival: An Assessment of the Prognosis of Patients at Time Points After Initial Diagnosis and Treatment of Locoregional Melanoma Metastasis. Journal of Clinical Oncology, 2017, 35, 1721-1729.	1.6	40
299	Telomere sequence content can be used to determine ALT activity in tumours. Nucleic Acids Research, 2018, 46, 4903-4918.	14.5	40
300	Comprehensive analysis of cutaneous and uveal melanoma liver metastases. , 2020, 8, e001501.		40
301	INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomas. Oncotarget, 2015, 6, 39891-39907.	1.8	40
302	Tumour Angiogenesis and p53 Protein Expression in Mammary Phyllodes Tumors. Modern Pathology, 2003, 16, 1007-1013.	5.5	39
303	Surgical Management of Melanoma Lung Metastasis: An Analysis of Survival Outcomes in 292 Consecutive Patients. Annals of Surgical Oncology, 2012, 19, 1774-1781.	1.5	39
304	Liver resection for metastatic melanoma: Equivalent survival for cutaneous and ocular primaries. Journal of Surgical Oncology, 2013, 108, 129-135.	1.7	39
305	Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy. Journal of the American Academy of Dermatology, 2015, 72, 809-815.e1.	1.2	39
306	Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making. Pathology, 2016, 48, 261-266.	0.6	39

#	Article	IF	CITATIONS
307	Imaging mass spectrometry assists in the classification of diagnostically challenging atypical Spitzoid neoplasms. Journal of the American Academy of Dermatology, 2016, 75, 1176-1186.e4.	1.2	38
308	Absence of Human Papillomavirus in Tonsillar Squamous Cell Carcinomas from Chinese Patients. American Journal of Pathology, 2003, 163, 2185-2189.	3.8	37
309	Effects of <scp>BRAF</scp> inhibitors on human melanoma tissue before treatment, early during treatment, and on progression. Pigment Cell and Melanoma Research, 2013, 26, 499-508.	3.3	37
310	Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma. Modern Pathology, 2015, 28, 884-894.	5.5	37
311	Morphologic Features of Melanophages Under In Vivo Reflectance Confocal Microscopy. Archives of Dermatology, 2010, 146, 492-8.	1.4	36
312	The retinoid signalling molecule, TRIM16, is repressed during squamous cell carcinoma skin carcinogenesis <i>in vivo</i> and reduces skin cancer cell migration <i>in vitro</i> . Journal of Pathology, 2012, 226, 451-462.	4.5	36
313	Reflectance confocal microscopy for diagnosis of mammary and extramammary Paget's disease. Journal of the European Academy of Dermatology and Venereology, 2013, 27, e24-9.	2.4	36
314	Outcome Following Sentinel Node Biopsy Plus Wide Local Excision Versus Wide Local Excision Only for Primary Cutaneous Melanoma. Annals of Surgery, 2014, 260, 149-157.	4.2	36
315	New evidence for geographic variation in the role of human papillomavirus in tonsillar carcinogenesis. Pathology, 2007, 39, 217-222.	0.6	35
316	Pathogenic mechanisms in the initiation and progression of mammary phyllodes tumours. Pathology, 2009, 41, 105-117.	0.6	35
317	Pathology Review Significantly Affects Diagnosis and Treatment of Melanoma Patients: An Analysis of 5011 Patients Treated at a Melanoma Treatment Center. Annals of Surgical Oncology, 2014, 21, 2245-2251.	1.5	35
318	Distinct Clinicopathological and Prognostic Features of Thin Nodular Primary Melanomas: An International Study from 17 Centers. Journal of the National Cancer Institute, 2019, 111, 1314-1322.	6.3	35
319	Replacement and desmoplastic histopathological growth patterns in cutaneous melanoma liver metastases: frequency, characteristics, and robust prognostic value. Journal of Pathology: Clinical Research, 2020, 6, 195-206.	3.0	35
320	Targeted BRAF Inhibition Impacts Survival in Melanoma Patients with High Levels of Wnt/β-Catenin Signaling. PLoS ONE, 2014, 9, e94748.	2.5	35
321	Cooperation between surgical oncologists and pathologists: a key element of multidisciplinary care for patients with cancer. Pathology, 2004, 36, 496-503.	0.6	34
322	Sentinel Node Positive Melanoma Patients: Prediction and Prognostic Significance of Nonsentinel Node Metastases and Development of a Survival Tree Model. Annals of Surgical Oncology, 2010, 17, 1995-2005.	1.5	34
323	Factors Predicting Recurrence and Survival in Sentinel Lymph Node-Positive Melanoma Patients. Annals of Surgery, 2011, 253, 1155-1164.	4.2	34
324	Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC) Journal of Clinical Oncology, 2019, 37, 9503-9503.	1.6	34

#	Article	IF	CITATIONS
325	Noxa upregulation by oncogenic activation of MEK/ERK through CREB promotes autophagy in human melanoma cells. Oncotarget, 2014, 5, 11237-11251.	1.8	34
326	Eccrine porocarcinoma of the upper eyelid. Australasian Journal of Dermatology, 2005, 46, 278-281.	0.7	33
327	Lymphatic biomarkers in primary melanomas as predictors of regional lymph node metastasis and patient outcomes. Pigment Cell and Melanoma Research, 2013, 26, 326-337.	3.3	33
328	Melanoma Patients with an Unknown Primary Tumor Site Have a Better Outcome than Those with a Known Primary Following Therapeutic Lymph Node Dissection for Macroscopic (Clinically Palpable) Nodal Disease. Annals of Surgical Oncology, 2014, 21, 3108-3116.	1.5	33
329	The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene. Science Translational Medicine, 2016, 8, 369ra177.	12.4	33
330	Neurotropic melanoma: an analysis of the clinicopathological features, management strategies and survival outcomes for 671 patients treated at a tertiary referral center. Modern Pathology, 2017, 30, 1538-1550.	5.5	33
331	Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients. Biomarker Research, 2017, 5, 32.	6.8	33
332	Tumour gene expression signature in primary melanoma predicts long-term outcomes. Nature Communications, 2021, 12, 1137.	12.8	33
333	Intramuscular dendritic fibromyxolipoma: Myxoid variant of spindle cell lipoma?. Pathology International, 2003, 53, 252-258.	1.3	32
334	Intraoperative Frozen-Section Evaluation Can Reduce Accuracy of Pathologic Assessment of Sentinel Nodes in Melanoma Patients. Journal of the American College of Surgeons, 2005, 201, 821-823.	0.5	32
335	Proteins from the Wnt pathway are involved in the pathogenesis and progression of mammary phyllodes tumours. Journal of Clinical Pathology, 2009, 62, 1016-1020.	2.0	32
336	Recent insights into the molecular pathogenesis of mammary phyllodes tumours. Journal of Clinical Pathology, 2013, 66, 496-505.	2.0	32
337	BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume. Molecular Cancer Therapeutics, 2015, 14, 1680-1692.	4.1	32
338	Estimated risk of progression of lentigo maligna to lentigo maligna melanoma. Melanoma Research, 2020, 30, 193-197.	1.2	32
339	Minimum Safe Pathologic Excision Margins for Primary Cutaneous Melanomas (1–2Âmm in Thickness): Analysis of 2131 Patients Treated at a Single Center. Annals of Surgical Oncology, 2016, 23, 1071-1081.	1.5	31
340	Poor Adherence to National Clinical Management Guidelines: A Population-Based, Cross-Sectional Study of the Surgical Management of Melanoma in New South Wales, Australia. Annals of Surgical Oncology, 2017, 24, 2080-2088.	1.5	31
341	TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells. Oncotarget, 2014, 5, 10127-10139.	1.8	31
342	Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas. Oncotarget, 2019, 10, 930-941.	1.8	31

#	Article	IF	CITATIONS
343	Total Sentinel Lymph Node Tumor Size Predicts Nonsentinel Node Metastasis and Survival in Patients with Melanoma. Annals of Surgical Oncology, 2010, 17, 3015-3020.	1.5	30
344	p16 and pRb immunohistochemical expression increases with increasing tumour grade in mammary phyllodes tumours. Histopathology, 2010, 56, 868-875.	2.9	30
345	BRM and BRG1 subunits of the SWI/SNF chromatin remodelling complex are downregulated upon progression of benign skin lesions into invasive tumours. British Journal of Dermatology, 2011, 164, 1221-1227.	1.5	30
346	Clinical and Pathologic Factors Associated with Distant Metastasis and Survival in Patients with Thin Primary Cutaneous Melanoma. Annals of Surgical Oncology, 2012, 19, 1782-1789.	1.5	30
347	BAP1 expression in cutaneous melanoma: a pilot study. Pathology, 2013, 45, 606-609.	0.6	30
348	Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage IIIB/C BRAF V600 mutant melanoma. Annals of Oncology, 2017, 28, v432.	1.2	30
349	Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence. Nature Cancer, 2020, 1, 197-209.	13.2	30
350	Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma. Cancer, 2012, 118, 4519-4529.	4.1	29
351	Lymphatic vessel density in primary melanomas predicts sentinel lymph node status and risk of metastasis. Histopathology, 2012, 61, 702-710.	2.9	29
352	Oncogenic suppression of PHLPP1 in human melanoma. Oncogene, 2014, 33, 4756-4766.	5.9	29
353	Germline BAP1 -positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy. European Journal of Cancer, 2018, 92, 48-53.	2.8	29
354	Diagnostic Accuracy of Fine Needle Biopsy for Metastatic Melanoma and Its Implications for Patient Management. Annals of Surgical Oncology, 2008, 15, 323-332.	1.5	28
355	Sentinel Node Status Prediction by Four Statistical Models. Annals of Surgery, 2009, 250, 964-969.	4.2	28
356	The important role of radiation treatment in the management of Merkel cell carcinoma. British Journal of Dermatology, 2013, 169, 975-982.	1.5	28
357	New <i>RAS</i> -Mutant Pancreatic Adenocarcinoma With Combined BRAF and MEK Inhibition for Metastatic Melanoma. Journal of Clinical Oncology, 2015, 33, e52-e56.	1.6	28
358	<i>BRAF</i> ^{V600E} and <i>NRAS</i> ^{Q61L/Q61R} mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting. Histopathology, 2016, 69, 680-686.	2.9	28
359	Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling. Clinical Cancer Research, 2018, 24, 4494-4504.	7.0	28
360	Subungual Melanoma of the Hand. Annals of Surgical Oncology, 2019, 26, 1035-1043.	1.5	28

#	Article	IF	CITATIONS
361	Development and Validation of Nomograms to Predict Local, Regional, and Distant Recurrence in Patients With Thin (T1) Melanomas. Journal of Clinical Oncology, 2021, 39, 1243-1252.	1.6	28
362	Failure to Remove True Sentinel Nodes Can Cause Failure of the Sentinel Node Biopsy Technique: Evidence from Antimony Concentrations in False-Negative Sentinel Nodes from Melanoma Patients. Annals of Surgical Oncology, 2004, 11, 174S-178S.	1.5	28
363	Rapid detection of metastatic melanoma in lymph nodes using proton magnetic resonance spectroscopy of fine needle aspiration biopsy specimens. Melanoma Research, 2003, 13, 259-261.	1.2	27
364	Argyrophilic Staining of Nucleolar Organizer Region Count and Morphometry in Benign and Malignant Melanocytic Lesions. American Journal of Dermatopathology, 2003, 25, 190-197.	0.6	27
365	LETTERS TO THE EDITOR. Australasian Journal of Dermatology, 2006, 47, 71-73.	0.7	27
366	Evaluation of the Clonal Origin of Multiple Primary Melanomas Using Molecular Profiling. Journal of Investigative Dermatology, 2009, 129, 1972-1982.	0.7	27
367	Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. Oncolmmunology, 2012, 1, 997-999.	4.6	27
368	Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naÃīve Melanoma Patients: Implications for Clinical Trials. Clinical Cancer Research, 2019, 25, 3247-3258.	7.0	27
369	Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma. Cancers, 2020, 12, 3374.	3.7	27
370	Association Between Melanoma Detected During Routine Skin Checks and Mortality. JAMA Dermatology, 2021, 157, 1425.	4.1	27
371	Spinal chloroma presenting with triplegia in an aleukaemic patient. Pathology, 2001, 33, 386-389.	0.6	26
372	Stromal nitric oxide synthase (NOS) expression correlates with the grade of mammary phyllodes tumour. Journal of Clinical Pathology, 2005, 58, 600-604.	2.0	26
373	Surgical Management of Primary Cutaneous Melanoma: Excision Margins and the Role of Sentinel Lymph Node Examination. Surgical Oncology Clinics of North America, 2006, 15, 301-318.	1.5	26
374	The molecular profile of metastatic melanoma in Australia. Pathology, 2016, 48, 188-193.	0.6	26
375	In Vivo Reflectance Confocal Microscopy for the Diagnosis of Melanoma and Melanotic Macules of the Lip. JAMA Dermatology, 2017, 153, 882.	4.1	26
376	Assessing the Potential for Patient-led Surveillance After Treatment of Localized Melanoma (MEL-SELF). JAMA Dermatology, 2022, 158, 33.	4.1	26
377	In vivo and ex vivo proton MR spectroscopy of primary and secondary melanoma. European Journal of Radiology, 2005, 53, 506-513.	2.6	25
378	Myxoid variant of adrenocortical carcinoma: Report of a unique case. Pathology International, 2006, 56, 89-94.	1.3	25

#	Article	IF	CITATIONS
379	Identification of <i>TFG</i> (TRKâ€fused gene) as a putative metastatic melanoma tumor suppressor gene. Genes Chromosomes and Cancer, 2012, 51, 452-461.	2.8	25
380	Atypical Spitzoid neoplasms. Melanoma Research, 2014, 24, 437-447.	1.2	25
381	Histological pattern of Merkel cell carcinoma sentinel lymph node metastasis improves stratification of Stage III patients. Modern Pathology, 2016, 29, 122-130.	5.5	25
382	Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases. Pathology, 2019, 51, 39-45.	0.6	25
383	Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor. Annals of Oncology, 2021, 32, 375-383.	1.2	25
384	Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis. Genome Medicine, 2021, 13, 81.	8.2	25
385	Cytologic Features of Metastatic and Recurrent Melanoma in Patients with Primary Cutaneous Desmoplastic Melanoma. American Journal of Clinical Pathology, 2008, 130, 715-723.	0.7	24
386	Treatment and Prognostic Significance of Positive Interval Sentinel Nodes in Patients with Primary Cutaneous Melanoma. Annals of Surgical Oncology, 2011, 18, 3292-3299.	1.5	24
387	Activating CYSLTR2 and PLCB4 Mutations in Primary Leptomeningeal Melanocytic Tumors. Journal of Investigative Dermatology, 2017, 137, 2033-2035.	0.7	24
388	Nicotinamide for skin cancer chemoprevention: effects of nicotinamide on melanoma in vitro and in vivo. Photochemical and Photobiological Sciences, 2020, 19, 171-179.	2.9	24
389	Targeting NK Cells to Enhance Melanoma Response to Immunotherapies. Cancers, 2021, 13, 1363.	3.7	24
390	Human 8-oxoguanine-DNA glycosylase-1 is downregulated in human basal cell carcinoma. Molecular Genetics and Metabolism, 2012, 106, 127-130.	1.1	23
391	Trajectories of premalignancy during the journey from melanocyte to melanoma. Pathology, 2018, 50, 16-23.	0.6	23
392	Evidence-Based Clinical Practice Guidelines for the Management of Patients with Lentigo Maligna. Dermatology, 2020, 236, 111-116.	2.1	23
393	Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. Journal of Clinical Oncology, 2020, 38, 1429-1441.	1.6	23
394	The deacylase SIRT5 supports melanoma viability by influencing chromatin dynamics. Journal of Clinical Investigation, 2021, 131, .	8.2	23
395	Micromorphometric Features of Positive Sentinel Lymph Nodes Predict Involvement of Nonsentinel Nodes in Patients With Melanoma. American Journal of Clinical Pathology, 2004, 122, 532-539.	0.7	23
396	The importance of mitotic rate as a prognostic factor for localized primary cutaneous melanoma. Journal of Cutaneous Pathology, 2006, 33, 395-396.	1.3	22

#	Article	IF	CITATIONS
397	An unusual variant of intraneural ganglion of the common peroneal nerve. Skeletal Radiology, 2006, 35, 165-171.	2.0	22
398	An extended antibody microarray for surface profiling metastatic melanoma. Journal of Immunological Methods, 2010, 358, 23-34.	1.4	22
399	Assessment of a new scoring system for predicting non-sentinel node positivity in sentinel node-positive melanoma patients. European Journal of Surgical Oncology, 2013, 39, 179-184.	1.0	22
400	Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma. Melanoma Research, 2015, 25, 91-94.	1.2	22
401	Targeting Nodal in Conjunction with Dacarbazine Induces Synergistic Anticancer Effects in Metastatic Melanoma. Molecular Cancer Research, 2015, 13, 670-680.	3.4	22
402	Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA. Cancers, 2020, 12, 2228.	3.7	22
403	Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab. , 2020, 8, e001488.		22
404	G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma. Clinical Cancer Research, 2021, 27, 2624-2635.	7.0	22
405	γδT Cells in Merkel Cell Carcinomas Have a Proinflammatory Profile Prognostic of Patient Survival. Cancer Immunology Research, 2021, 9, 612-623.	3.4	22
406	Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma. Annals of Oncology, 2021, 32, 766-777.	1.2	22
407	Association of Antithyroid Antibodies in Checkpoint Inhibitor–Associated Thyroid Immune–Related Adverse Events. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e1843-e1849.	3.6	22
408	Immunohistochemical stains fail to increase the detection rate of micrometastatic melanoma in completion regional lymph node dissection specimens. Melanoma Research, 2004, 14, 263-268.	1.2	21
409	High molecular weight-melanoma-associated antigen as a biomarker of desmoplastic melanoma. Pigment Cell and Melanoma Research, 2010, 23, 137-140.	3.3	21
410	The absence of <scp>B</scp> rm exacerbates photocarcinogenesis. Experimental Dermatology, 2012, 21, 599-604.	2.9	21
411	LNK suppresses interferon signaling in melanoma. Nature Communications, 2019, 10, 2230.	12.8	21
412	Correlation Between Surgical and Histologic Margins in Melanoma Wide Excision Specimens. Annals of Surgical Oncology, 2019, 26, 25-32.	1.5	21
413	The steadily growing problem of lentigo maligna and lentigo maligna melanoma in Australia: Populationâ€based data on diagnosis and management. Australasian Journal of Dermatology, 2019, 60, 118-125.	0.7	21
414	The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence. British Journal of Cancer, 2021, 124, 156-160.	6.4	21

#	Article	IF	CITATIONS
415	The tumour immune landscape and its implications in cutaneous melanoma. Pigment Cell and Melanoma Research, 2021, 34, 529-549.	3.3	21
416	Association of Histologic Regression With a Favorable Outcome in Patients With Stage 1 and Stage 2 Cutaneous Melanoma. JAMA Dermatology, 2021, 157, 166.	4.1	21
417	LBA3 Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial. Annals of Oncology, 2021, 32, S1314-S1315.	1.2	21
418	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). Annals of Surgical Oncology, 2022, 29, 3694-3708.	1.5	21
419	Melanocytic lesions of the face: diagnostic pitfalls. Annals of the Academy of Medicine, Singapore, 2004, 33, 3-14.	0.4	21
420	Sentinel lymph nodes in malignant melanoma: Extended histopathologic evaluation improves diagnostic precision. Cancer, 2004, 101, 2141-2142.	4.1	20
421	Melanoma Metastases in Regional Lymph Nodes Are Accurately Detected by Proton Magnetic Resonance Spectroscopy of Fine-Needle Aspirate Biopsy Samples. Annals of Surgical Oncology, 2005, 12, 943-949.	1.5	20
422	Survival in Patients With Desmoplastic Melanoma. Journal of Clinical Oncology, 2006, 24, e12-e12.	1.6	20
423	Sentinel lymph node biopsy for melanoma: aspects of pathologic assessment. Future Oncology, 2008, 4, 535-551.	2.4	20
424	Merkel cell carcinoma with fibrosarcomatous differentiation. Pathology, 2008, 40, 314-316.	0.6	20
425	Fine-needle biopsy of metastatic melanoma: clinical use and new applications. Lancet Oncology, The, 2010, 11, 391-400.	10.7	20
426	Reproducibility of AJCC Staging Parameters in Primary Cutaneous Melanoma: An Analysis of 4,924 Cases. Annals of Surgical Oncology, 2013, 20, 3969-3975.	1.5	20
427	A novel hypoxia-associated subset of FN1highMITFlow melanoma cells: identification, characterization, and prognostic value. Modern Pathology, 2014, 27, 1088-1100.	5.5	20
428	Incidence of New Primary Melanomas After Diagnosis of Stage III and IV Melanoma. Journal of Clinical Oncology, 2014, 32, 816-823.	1.6	20
429	Sex Differences in Melanoma Survival are Not Related to Mitotic Rate of the Primary Tumor. Annals of Surgical Oncology, 2015, 22, 1598-1603.	1.5	20
430	Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis. Clinical and Experimental Immunology, 2020, 202, 335-352.	2.6	20
431	Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients. Frontiers in Immunology, 2020, 11, 372.	4.8	20
432	Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma. JAMA Surgery, 2022, 157, 335.	4.3	20

#	Article	IF	CITATIONS
433	Sentinel node biopsy for melanoma: Where have we been and where are we going?. Annals of Surgical Oncology, 2004, 11, 147S-151S.	1.5	19
434	Low meprin expression differentiates primary ovarian mucinous carcinoma from gastrointestinal cancers that commonly metastasise to the ovaries. Journal of Clinical Pathology, 2007, 60, 622-626.	2.0	19
435	Melanoma Pathology: Important Issues for Clinicians Involved in the Multidisciplinary Care of Melanoma Patients. Surgical Oncology Clinics of North America, 2011, 20, 19-37.	1.5	19
436	Clinical and pathological features of metastases of primary cutaneous desmoplastic melanoma. Histopathology, 2011, 58, 886-895.	2.9	19
437	Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas. Pathology, 2014, 46, 193-198.	0.6	19
438	Role of frozen section analysis in nodular thyroid pathology. European Annals of Otorhinolaryngology, Head and Neck Diseases, 2015, 132, 67-70.	0.7	19
439	Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists. Pathology, 2016, 48, 194-202.	0.6	19
440	Detection of desmoplastic melanoma with dermoscopy and reflectance confocal microscopy. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 2016-2024.	2.4	19
441	Mutation load in melanoma is affected by <i><scp>MC</scp>1R</i> genotype. Pigment Cell and Melanoma Research, 2017, 30, 255-258.	3.3	19
442	The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma Journal of Clinical Oncology, 2022, 40, TPS9605-TPS9605.	1.6	19
443	Antimony by ICP-MS as a marker for sentinel lymph nodes in melanoma patients. Analyst, The, 2003, 128, 217-219.	3.5	18
444	Parachordoma is not distinguishable from axial chordoma using immunohistochemistry. Pathology International, 2004, 54, 364-370.	1.3	18
445	The history and future of melanoma staging. Journal of Surgical Oncology, 2004, 86, 224-235.	1.7	18
446	Histological expression of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in human primary melanoma. Pathology, 2004, 36, 561-565.	0.6	18
447	Targeted Therapy Database (TTD): A Model to Match Patient's Molecular Profile with Current Knowledge on Cancer Biology. PLoS ONE, 2010, 5, e11965.	2.5	18
448	p16 <scp>^{INK}</scp> ^{4a} deficiency promotes <scp>DNA</scp> hyperâ€replication and genetic instability in melanocytes. Pigment Cell and Melanoma Research, 2013, 26, 236-246.	3.3	18
449	Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors. Modern Pathology, 2014, 27, 1193-1202.	5.5	18
450	Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. Annals of Oncology, 2020, 31, 1569-1579.	1.2	18

#	Article	IF	CITATIONS
451	Brain metastasis DNA methylomes, a novel resource for the identification of biological and clinical features. Scientific Data, 2018, 5, 180245.	5.3	18
452	Twenty-four months RFS and updated toxicity data from OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in stage III melanoma Journal of Clinical Oncology, 2020, 38, 10015-10015.	1.6	18
453	Polymorphous Low-Grade Adenocarcinoma in the Lung: A Case Report. International Journal of Surgical Pathology, 2004, 12, 287-292.	0.8	17
454	Antimony concentrations in nodal tissue can confirm sentinel node identity. Modern Pathology, 2004, 17, 1191-1197.	5.5	17
455	Selective Sentinel Lymphadenectomy: Progress to Date and Prospects for the Future. Cancer Treatment and Research, 2005, 127, 269-287.	0.5	17
456	Clinical relevance of melanoma micrometastases in sentinel nodes: too early to tell. Annals of Oncology, 2007, 18, 806-808.	1.2	17
457	Involvement of α―and βâ€catenins and Eâ€cadherin in the development of mammary phyllodes tumours. Histopathology, 2012, 61, 667-674.	2.9	17
458	Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications. Cancer Microenvironment, 2015, 8, 111-118.	3.1	17
459	Breslow Thickness Measurements of Melanomas Around American Joint Committee on Cancer Staging Cut-Off Points: Imprecision and Terminal Digit Bias Have Important Implications for Staging and Patient Management. Annals of Surgical Oncology, 2016, 23, 2658-2663.	1.5	17
460	Extranodal Spread is Associated with Recurrence and Poor Survival in Stage III Cutaneous Melanoma Patients. Annals of Surgical Oncology, 2017, 24, 1378-1385.	1.5	17
461	A Review of Key Biological and Molecular Events Underpinning Transformation of Melanocytes to Primary and Metastatic Melanoma. Cancers, 2019, 11, 2041.	3.7	17
462	A Reduction in Inflammatory Macrophages May Contribute to Skin Cancer Chemoprevention by Nicotinamide. Journal of Investigative Dermatology, 2019, 139, 467-469.	0.7	17
463	Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C Inhibition. Cancers, 2021, 13, 1740.	3.7	17
464	Pitfalls and important issues in the pathologic diagnosis of melanocytic tumors. Ochsner Journal, 2010, 10, 66-74.	1.1	17
465	Use of multiple cytometric markers improves discrimination between benign and malignant melanocytic lesions. Melanoma Research, 2003, 13, 581-586.	1.2	16
466	Melanocytic nevus with focal atypical epithelioid components (clonal nevus) is a combined nevus. Journal of the American Academy of Dermatology, 2007, 56, 889-890.	1.2	16
467	E-cadherin expression in the epithelial components of mammary phyllodes tumors. Human Pathology, 2012, 43, 2117-2123.	2.0	16
468	Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients. Pigment Cell and Melanoma Research, 2014, 27, 1106-1116.	3.3	16

#	Article	IF	CITATIONS
469	BAP1-inactivated Spitzoid Naevi. American Journal of Surgical Pathology, 2015, 39, 722.	3.7	16
470	SOX10 expression in cutaneous scars: a potential diagnostic pitfall in the evaluation of melanoma re-excision specimens. Pathology, 2016, 48, 626-628.	0.6	16
471	18-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant (neoadj) ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma. Annals of Oncology, 2019, 30, v910.	1.2	16
472	Inter―and intrapatient heterogeneity of indoleamine 2,3â€dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment. Histopathology, 2019, 74, 817-828.	2.9	16
473	Temporal and spatial modulation of the tumor and systemic immune response in the murine Gl261 glioma model. PLoS ONE, 2020, 15, e0226444.	2.5	16
474	Lentiginous melanoma (lentigo maligna and lentigo maligna melanoma) in Australia: clinicopathological characteristics, management and recurrence rates after 10â€year followâ€up at a tertiary centre. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1315-1322.	2.4	16
475	Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma. European Journal of Cancer, 2021, 148, 51-57.	2.8	16
476	Impact of Next-generation Sequencing on Interobserver Agreement and Diagnosis of Spitzoid Neoplasms. American Journal of Surgical Pathology, 2021, 45, 1597-1605.	3.7	16
477	Histological regression in melanoma: impact on sentinel lymph node status and survival. Modern Pathology, 2021, 34, 1999-2008.	5.5	16
478	Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial Journal of Clinical Oncology, 2019, 37, TPS9605-TPS9605.	1.6	16
479	Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy. , 2022, 10, e004771.		16
480	NeoTrio: Randomized trial of neoadjuvant (NAT) pembrolizumab (Pembro) alone, in sequence (SEQ) with, or concurrent (CON) with dabrafenib plus trametinib (D+T) in resectable BRAF-mutant stage III melanoma to determine optimal combination of therapy Journal of Clinical Oncology, 2022, 40, 9503-9503.	1.6	16
481	Myoid Angioendothelioma of the Spleen. International Journal of Surgical Pathology, 2004, 12, 51-56.	0.8	15
482	Epidermolysis bullosa acquisita requiring multiple oesophageal dilatations. Clinical and Experimental Dermatology, 2008, 33, 787-789.	1.3	15
483	Pigmented epithelioid melanocytoma: a recently described melanocytic tumour of low malignant potential. Pathology, 2010, 42, 284-286.	0.6	15
484	Peritoneal melanosis associated with metastatic melanoma involving the omentum. Pathology, 2012, 44, 255-257.	0.6	15
485	Digital papillary adenocarcinoma: a tumour that should be considered in the differential diagnosis of neoplasms involving the digits. Pathology, 2013, 45, 55-61.	0.6	15
486	First interim analysis of a randomised trial of whole brain radiotherapy in melanoma brain metastases confirms high data quality. BMC Research Notes, 2015, 8, 192.	1.4	15

#	Article	IF	CITATIONS
487	Classification of high risk basal cell carcinoma subtypes: experience of the ONTRAC study with proposed definitions and guidelines for pathological reporting. Pathology, 2016, 48, 395-397.	0.6	15
488	Melanoma protective antitumor immunity activated by catalytic DNA. Oncogene, 2018, 37, 5115-5126.	5.9	15
489	Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma. Journal of Clinical Investigation, 2021, 131, .	8.2	15
490	The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment. Lung Cancer, 2022, 165, 124-132.	2.0	15
491	Epiphyseal osteoblastoma-like osteosarcoma. Skeletal Radiology, 2004, 33, 46-50.	2.0	14
492	Endocrine mucin producing sweat gland carcinoma: a clinicopathological analysis of three cases. Pathology, 2012, 44, 568-571.	0.6	14
493	5â€Hydroxymethylcytosine is a nuclear biomarker to assess biological potential in histologically ambiguous heavily pigmented melanocytic neoplasms. Journal of Cutaneous Pathology, 2017, 44, 249-255.	1.3	14
494	Targeting melanoma with front-line therapy does not abrogate Nodal-expressing tumor cells. Laboratory Investigation, 2017, 97, 176-186.	3.7	14
495	The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma. Frontiers in Oncology, 2018, 8, 584.	2.8	14
496	Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma. Cancers, 2019, 11, 1905.	3.7	14
497	Reappraisal of the prognostic significance of mitotic rate supports its reincorporation into the melanoma staging system. Cancer, 2020, 126, 4717-4725.	4.1	14
498	Genetic drivers of non utaneous melanomas: Challenges and opportunities in a heterogeneous landscape. Experimental Dermatology, 2022, 31, 13-30.	2.9	14
499	Desmoplastic melanoma: a review of its pathology and clinical behaviour, and of management recommendations in published guidelines. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1290-1298.	2.4	14
500	Predicting sentinel node positivity in patients with melanoma: external validation of a riskâ€prediction calculator (the Melanoma Institute Australia nomogram) using a large European populationâ€based patient cohort*. British Journal of Dermatology, 2021, 185, 412-418.	1.5	14
501	Hepatocellular carcinoma metastasizing to the orbit diagnosed by fine needle aspiration cytology. Pathology, 1999, 31, 350-353.	0.6	13
502	Failure to remove true sentinel nodes can cause failure of the sentinel node biopsy technique: Evidence from antimony concentrations in false-negative sentinel nodes from melanoma patients. Annals of Surgical Oncology, 2004, 11, 174S-178S.	1.5	13
503	Lymphoma occurring in patients with cutaneous melanoma. Journal of Clinical Pathology, 2010, 63, 777-781.	2.0	13
504	Melanotic schwannoma mimicking metastatic pigmented melanoma: a pitfall in cytological diagnosis. Pathology, 2010, 42, 287-289.	0.6	13

#	Article	IF	CITATIONS
505	The diagnostic value of adding dynamic scintigraphy to standard delayed planar imaging for sentinel node identification in melanoma patients. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1999-2004.	6.4	13
506	Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (<0.1Âmm) Sentinel Lymph Node Metastases. Annals of Surgical Oncology, 2015, 22, 2972-2977.	1.5	13
507	The regenerating naevus. Pathology, 2016, 48, 108-112.	0.6	13
508	RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells. Scientific Reports, 2018, 8, 653.	3.3	13
509	Sentinel lymph node biopsy in patients with thin melanomas: Frequency and predictors of metastasis based on analysis of two large international cohorts. Journal of Surgical Oncology, 2018, 118, 599-605.	1.7	13
510	Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas. Cancer Immunology Research, 2020, 8, 1346-1353.	3.4	13
511	The prognostic significance of microsatellites in cutaneous melanoma. Modern Pathology, 2020, 33, 1369-1379.	5.5	13
512	A multicentre study of naevusâ€associated melanoma vs. <i>de novo</i> melanoma, tumour thickness and body site differences*. British Journal of Dermatology, 2021, 185, 101-109.	1.5	13
513	PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma. Frontiers in Immunology, 2021, 12, 672521.	4.8	13
514	Aggressive endometriosis: report of a case. International Journal of Gynecological Cancer, 2000, 10, 257-262.	2.5	13
515	Unusual case of subcutaneous panniculitis-like T-cell lymphoma. Australasian Journal of Dermatology, 2004, 45, 114-118.	0.7	12
516	Endothelin-1 expression correlates with atypical histological features in mammary phyllodes tumours. Journal of Clinical Pathology, 2006, 60, 1051-1056.	2.0	12
517	Epithelioid and spindle cell haemangioma of bone. Skeletal Radiology, 2007, 36, 50-57.	2.0	12
518	Re-evaluation of a Scoring System to Predict Nonsentinel-Node Metastasis and Prognosis in Melanoma Patients. Journal of the American College of Surgeons, 2010, 211, 522-525.	0.5	12
519	Disturbed protein–protein interaction networks in metastatic melanoma are associated with worse prognosis and increased functional mutation burden. Pigment Cell and Melanoma Research, 2013, 26, 708-722.	3.3	12
520	The Optimum Excision Margin and Regional Node Management for Primary Cutaneous T3 Melanomas (2–4 mm in Thickness). Annals of Surgery, 2014, 260, 1095-1102.	4.2	12
521	Atypical Ewing sarcoma breakpoint region 1 fluorescence <i>inâ€situ</i> hybridization signal patterns in bone and soft tissue tumours: diagnostic experience with 135 cases. Histopathology, 2016, 69, 1000-1011.	2.9	12
522	InÂvivo reflectance confocal microscopy for evaluating melanoma of the lip and its differential diagnoses. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2017, 123, 84-94.	0.4	12

#	Article	IF	CITATIONS
523	Not all melanomas are created equal: a review and call for more research into nodular melanoma. British Journal of Dermatology, 2021, 185, 700-710.	1.5	12
524	Do we need to rethink the diagnoses melanoma <i>in situ</i> and severely dysplastic naevus?. British Journal of Dermatology, 2022, 186, 1030-1032.	1.5	12
525	Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithms. EBioMedicine, 2022, 82, 104143.	6.1	12
526	Frontiers in melanocytic pathology. Pathology, 2004, 36, 385-386.	0.6	11
527	Borderline lepromatous leprosy presenting as a single cutaneous plaque. Australasian Journal of Dermatology, 2005, 46, 181-183.	0.7	11
528	The Prognostic Significance of Isolated Immunohistochemically Positive Cells in Sentinel Lymph Nodes of Melanoma Patients. American Journal of Surgical Pathology, 2008, 32, 1106-1107.	3.7	11
529	Melanoma exhibiting cartilaginous differentiation. Histopathology, 2010, 56, 815-821.	2.9	11
530	Computer-assisted diagnosis for skin cancer: have we been outsmarted?. Lancet, The, 2017, 389, 1962-1964.	13.7	11
531	Recurrent bowel obstruction: unusual presentation of pembrolizumab-induced pancreatitis in annular pancreas. European Journal of Cancer, 2017, 82, 167-170.	2.8	11
532	Germline BAP1 mutations also predispose to cutaneous squamous cell carcinoma. Pathology, 2017, 49, 539-542.	0.6	11
533	Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing. Biomarker Research, 2017, 5, 17.	6.8	11
534	Prognostic Significance of Periadnexal Extension in Cutaneous Melanoma and its Implications for Pathologic Reporting and Staging. American Journal of Surgical Pathology, 2018, 42, 359-366.	3.7	11
535	FISH analysis of selected soft tissue tumors: Diagnostic experience in a tertiary center. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 38-47.	1.1	11
536	Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. Cancer Medicine, 2020, 9, 8650-8661.	2.8	11
537	Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density With Clinical Response to BRAF Inhibitors. Frontiers in Oncology, 2020, 10, 757.	2.8	11
538	Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/â^' Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets. Cancers, 2021, 13, 3186.	3.7	11
539	Response to anti-PD1/PDL1 therapy in patients with metastatic desmoplastic melanoma Journal of Clinical Oncology, 2015, 33, 9011-9011.	1.6	11
540	Preliminary results from the international neoadjuvant melanoma consortium (INMC) Journal of Clinical Oncology, 2017, 35, 9581-9581.	1.6	11

#	Article	IF	CITATIONS
541	Multi-Trait Genetic Analysis Identifies Autoimmune Loci Associated with Cutaneous Melanoma. Journal of Investigative Dermatology, 2022, 142, 1607-1616.	0.7	11
542	Dermoscopic features and screening strategies for the detection of smallâ€diameter melanomas. Clinical and Experimental Dermatology, 2022, 47, 932-941.	1.3	11
543	Condylomata acuminata of the urinary bladder with HPV 11. Pathology, 2005, 37, 176-178.	0.6	10
544	Biospecimen banking: The pathway to personalized medicine for patients with cancer. Journal of Surgical Oncology, 2013, 107, 681-682.	1.7	10
545	The prognostic value of tumor mitotic rate in children and adolescents with cutaneous melanoma: A retrospective cohort study. Journal of the American Academy of Dermatology, 2020, 82, 910-919.	1.2	10
546	Molecular Profiling of Noncoding Mutations Distinguishes Nevoid Melanomas From Mitotically Active Nevi in Pregnancy. American Journal of Surgical Pathology, 2020, 44, 357-367.	3.7	10
547	Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow-up? A protocol for the MEL-SELF randomised controlled trial. Trials, 2021, 22, 324.	1.6	10
548	The Role of Intra-operative Pathological Evaluation in the Management of Musculoskeletal Tumours. Recent Results in Cancer Research, 2009, 179, 11-24.	1.8	10
549	A multi-step classifier addressing cohort heterogeneity improves performance of prognostic biomarkers in three cancer types. Oncotarget, 2017, 8, 2807-2815.	1.8	10
550	Primary Melanoma of the Lung. , 2006, , 293-297.		9
551	Cytological features of melanoma in exfoliative fluid specimens. Journal of Clinical Pathology, 2009, 62, 638-643.	2.0	9
552	The Prognostic Value of Tumor Mitotic Rate and Other Clinicopathologic Factors in Patients with Locoregional Recurrences of Melanoma. Annals of Surgical Oncology, 2010, 17, 2992-2999.	1.5	9
553	Selective Loss of Wild-Type p16INK4a Expression in Human Nevi. Journal of Investigative Dermatology, 2011, 131, 2329-2332.	0.7	9
554	Intra-patient heterogeneity of BRAF mutation status: fact or fiction?. British Journal of Cancer, 2014, 111, 1678-1679.	6.4	9
555	Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes. Pathology, 2015, 47, 683-693.	0.6	9
556	Multiple checkpoints on the long road towards cancer immunotherapy. Immunology and Cell Biology, 2015, 93, 323-325.	2.3	9
557	OpACIN-neo: A multicenter phase II study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO). Annals of Oncology, 2018, 29, viii734.	1.2	9
558	Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis. British Journal of Cancer, 2018, 119, 713-723.	6.4	9

#	Article	IF	CITATIONS
559	Multiplex melanoma families are enriched for polygenic risk. Human Molecular Genetics, 2020, 29, 2976-2985.	2.9	9
560	GLI activated epithelioid cell tumour: report of a case and proposed new terminology. Pathology, 2021, 53, 267-270.	0.6	9
561	Melanoma In Situ: A Critical Review and Re-Evaluation of Current Excision Margin Recommendations. Advances in Therapy, 2021, 38, 3506-3530.	2.9	9
562	Evaluation of Crizotinib Treatment in a Patient With Unresectable <i>GOPC-ROS1</i> Fusion Agminated Spitz Nevi. JAMA Dermatology, 2021, 157, 836-841.	4.1	9
563	Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage iiib/c BRAF-V600 mutation positive melanoma Journal of Clinical Oncology, 2016, 34, 9583-9583.	1.6	9
564	Personalized combination of neoadjuvant domatinostat, nivolumab and ipilimumab in macroscopic stage III melanoma patients stratified according to the interferon-gamma signature: The DONIMI study Journal of Clinical Oncology, 2020, 38, TPS10087-TPS10087.	1.6	9
565	Improving diagnostic accuracy for suspicious melanocytic skin lesions: New Australian melanoma clinical practice guidelines stress the importance of clinician/pathologist communication. Australian Journal of General Practice, 2019, 48, 357-362.	0.8	9
566	Validation of an Accurate Automated Multiplex Immunofluorescence Method for Immuno-Profiling Melanoma. Frontiers in Molecular Biosciences, 2022, 9, .	3.5	9
567	The site of infection and ethnicity of the patient influence the biological pathways to HPV-induced mucosal cancer. Modern Pathology, 2004, 17, 1031-1037.	5.5	8
568	Confirmation of Sentinel Lymph Node Identity by Analysis of Fine-Needle Biopsy Samples Using Inductively Coupled Plasma–Mass Spectrometry. Annals of Surgical Oncology, 2008, 15, 934-940.	1.5	8
569	Tumoural calcium pyrophosphate dihydrate crystal deposition disease (tophaceous pseudogout) of the hand: a report of two cases including one with a previously unreported associated florid reactive myofibroblastic proliferation. Pathology, 2008, 40, 719-722.	0.6	8
570	Radiation Recall Dermatitis After Pre-Sensitization With Pegylated Liposomal Doxorubicin. Cancer Investigation, 2009, 27, 397-401.	1.3	8
571	Synchronous and metachronous malignancies in patients with melanoma: a clinicopathologic study highlighting the role of fine-needle biopsy cytology and potential diagnostic pitfalls. Melanoma Research, 2010, 20, 203-211.	1.2	8
572	Aberrant hypermethylation in primary tumours and sentinel lymph node metastases in paediatric patients with cutaneous melanoma. British Journal of Dermatology, 2012, 166, 1319-1326.	1.5	8
573	Eruptive disseminated <scp>S</scp> pitz naevus (<scp>EDSN</scp>) in a young girl of Indian origin. Australasian Journal of Dermatology, 2015, 56, 134-136.	0.7	8
574	Lethal melanoma in children: a clinicopathological study of 12 cases. Pathology, 2016, 48, 705-711.	0.6	8
575	Melanoma diagnosis may be a pitfall for optical coherence tomography assessment of equivocal amelanotic or hypomelanotic skin lesions. British Journal of Dermatology, 2017, 177, 574-577.	1.5	8
576	Programmed Death-Ligand 1 Expression in a Large Cohort of Pediatric Patients With Solid Tumor and Association With Clinicopathologic Features in Neuroblastoma. JCO Precision Oncology, 2017, 1, 1-12.	3.0	8

#	Article	IF	CITATIONS
577	Oral malignant gastrointestinal neuroectodermal tumour with junctional component mimicking mucosal melanoma. Pathology, 2018, 50, 648-653.	0.6	8
578	Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma. Annals of Surgical Oncology, 2021, 28, 6109-6123.	1.5	8
579	Abstract 3412: 36-months and 18-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients - update of the OpACIN and OpACIN-neo trials. Cancer Research, 2020, 80, 3412-3412.	0.9	8
580	Adjuvant radiotherapy after lymphadenectomy in melanoma patients: Final results of an intergroup randomized trial (ANZMTG 0.1.02/TROG 02.01) Journal of Clinical Oncology, 2013, 31, 9001-9001.	1.6	8
581	Determining optimal sequencing of anti-PD-1 and BRAF-targeted therapy: A phase II randomised study of neoadjuvant pembrolizumab with/without dabrafenib and trametinib (D+T) in BRAF V600 mutant resectable stage IIIb/c/d melanoma (NeoTrio trial) Journal of Clinical Oncology, 2018, 36, TPS9604-TPS9604.	1.6	8
582	Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo) Journal of Clinical Oncology, 2018, 36, TPS9606-TPS9606.	1.6	8
583	High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy. Genes, 2021, 12, 1629.	2.4	8
584	Survival update of neoadjuvant ipilimumab + nivolumab in macroscopic stage III melanoma: The OpACIN and OpACIN-neo trials Journal of Clinical Oncology, 2022, 40, 9572-9572.	1.6	8
585	The interferon-gamma (IFN-y) signature from baseline tumor material predicts pathologic response after neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma Journal of Clinical Oncology, 2022, 40, 9539-9539.	1.6	8
586	Surgical Strategies and Histopathologic Issues in the Management of Lentigo Maligna. Annals of Surgical Oncology, 2009, 16, 1456-1458.	1.5	7
587	Diagnostic value of 8.5 T magnetic resonance spectroscopy of benign and malignant skin lesion biopsies. Melanoma Research, 2010, 20, 311-317.	1.2	7
588	Can We Better Identify Thin Cutaneous Melanomas That are Likely to Metastasize and Cause Death?. Annals of Surgical Oncology, 2012, 19, 3310-3312.	1.5	7
589	Mitotic rate in melanoma should be recorded as the number of mitoses per mm2 (not per high power) Tj ETQq1 1	0.78431 1.8	4 rgBT /Overl
590	Controversies and evolving concepts in the diagnosis, classification and management of lentigo maligna. Expert Review of Dermatology, 2013, 8, 195-214.	0.3	7
591	Predicting recurrence in patients with sentinel node-negative melanoma: validation of the EORTC nomogram using population-based data. British Journal of Surgery, 2021, 108, 550-553.	0.3	7
592	Melanoma with osseous or chondroid differentiation: a report of eight cases including SATB2 expression and mutation analysis. Pathology, 2021, 53, 830-835.	0.6	7
593	Conditional survival estimates for cancer patients. Oncotarget, 2017, 8, 84639-84640.	1.8	7
594	Sentinel lymph node melanoma metastases: Assessment of tumor burden for clinical prediction of outcome in the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). European Journal of Surgical Oncology, 2022, 48, 1280-1287.	1.0	7

#	Article	IF	CITATIONS
595	Characterization of the treatment-naive immune microenvironment in melanoma with <i>BRAF</i> mutation. , 2022, 10, e004095.		7
596	Middle lobe syndrome due to obstructing solitary bronchial papilloma. Australian and New Zealand Journal of Medicine, 1999, 29, 745-747.	0.5	6
597	Acute basophilic leukemia presenting with abnormal liver function tests and the absence of blast cells in the peripheral blood. Pathology, 2000, 32, 52-55.	0.6	6
598	Pagetoid spread of melanocytes in Spitz naevi: authors' reply. Pathology, 2002, 34, 591.	0.6	6
599	Progressive visual loss in a patient with presumed temporal arteritis despite treatment: how to make the diagnosis. Clinical and Experimental Ophthalmology, 2004, 32, 335-336.	2.6	6
600	Atypical fibroxanthoma: differential diagnosis from other sarcomatoid skin lesions. Diagnostic Histopathology, 2010, 16, 401-408.	0.4	6
601	Identification of new prognostic biomarkers for Stage III metastatic melanoma patients. Oncolmmunology, 2013, 2, e25564.	4.6	6
602	Surface antigen profiles of leukocytes and melanoma cells in lymph node metastases are associated with survival in AJCC stage III melanoma patients. Clinical and Experimental Metastasis, 2014, 31, 407-421.	3.3	6
603	3305 PD1 inhibition-induced changes in melanoma and its associated immune infiltrate. European Journal of Cancer, 2015, 51, S666.	2.8	6
604	Surgical management of the neck in patients with metastatic melanoma in parotid lymph nodes. Journal of Surgical Oncology, 2019, 120, 1462-1469.	1.7	6
605	Embracing changes to the American Joint Committee on Cancer 8th edition melanoma staging system. European Journal of Cancer, 2019, 112, 9-11.	2.8	6
606	Hypermethylation of Circulating Free DNA in Cutaneous Melanoma. Applied Sciences (Switzerland), 2019, 9, 5074.	2.5	6
607	From Breslow to BRAF and immunotherapy: evolving concepts in melanoma pathogenesis and disease progression and their implications for changing management over the last 50 years. Human Pathology, 2020, 95, 149-160.	2.0	6
608	Identifying challenges to implementation of clinical practice guidelines for sentinel lymph node biopsy in patients with melanoma in Australia: protocol paper for a mixed methods study. BMJ Open, 2020, 10, e032636.	1.9	6
609	Targeting the Microbiome to Overcome Resistance. Cancer Cell, 2021, 39, 151-153.	16.8	6
610	Abstract 5734: Gut microbiota predicts response and toxicity with neoadjuvant immunotherapy. , 2020, , .		6
611	Morphologic and immunohistochemical (IHC) changes in metastatic melanoma (MM) tissue and associations with clinical outcome in patients (pts) on BRAF inhibitors (BRAFi) Journal of Clinical Oncology, 2011, 29, 8542-8542.	1.6	6
612	Neoadjuvant BRAF (dabrafenib) and MEK (trametinib) inhibition for high-risk resectable stage III and IV melanoma Journal of Clinical Oncology, 2015, 33, TPS9091-TPS9091.	1.6	6

#	Article	IF	CITATIONS
613	A randomized phase 2 study of nivolumab and nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases: The Anti-PD1 Brain Collaboration (ABC Study) Journal of Clinical Oncology, 2016, 34, TPS9591-TPS9591.	1.6	6
614	Melanoma - a management guide for GPs. Australian Family Physician, 2012, 41, 470-3.	0.5	6
615	Hyalinising spindle cell tumour with giant rosettes: report of a case with unusual features including original histological and ultrastructural observations. Pathology, 2001, 33, 101-107.	0.6	5
616	Paratesticular rhabdomyoma. Pathology, 2007, 39, 367-369.	0.6	5
617	Prognostic significance of histopathological parameters in sentinel nodes of melanoma patients. Histopathology, 2008, 52, 242-242.	2.9	5
618	Prognostic significance of histopathological parameters in sentinel nodes of melanoma patients. Histopathology, 2008, 53, 345-345.	2.9	5
619	Fine-needle biopsy as a diagnostic technique for metastatic melanoma. Expert Opinion on Medical Diagnostics, 2008, 2, 1-10.	1.6	5
620	Location of Melanoma Metastases in Sentinel Lymph Nodes: What are the Implications for Histologic Processing of Sentinel Lymph Nodes in Routine Practice?. American Journal of Surgical Pathology, 2010, 34, 127-129.	3.7	5
621	Cellular blue naevus involving the urinary bladder. Pathology, 2012, 44, 664-668.	0.6	5
622	Primary oesophageal melanoma - a case report. World Journal of Surgical Oncology, 2014, 12, 77.	1.9	5
623	How anti-PD1 treatments are changing the management of melanoma. Melanoma Management, 2014, 1, 165-172.	0.5	5
624	The "Tricky Business―of Identifying Mechanisms of Resistance to Anti–PD-1. Clinical Cancer Research, 2017, 23, 2921-2923.	7.0	5
625	Punch †scoring': a technique that facilitates melanoma diagnosis of clinically suspicious pigmented lesions. Histopathology, 2018, 72, 294-304.	2.9	5
626	External validation of a prognostic model to predict survival of patients with sentinel node-negative melanoma. British Journal of Surgery, 2019, 106, 1319-1326.	0.3	5
627	Publication metrics: what do they mean?. Pathology, 2020, 52, 619-620.	0.6	5
628	Primary dermal melanoma: clinical behaviour, prognosis and treatment. European Journal of Surgical Oncology, 2020, 46, 2131-2139.	1.0	5
629	Clinical outcomes following surgical treatment of lentigo maligna of the head and neck. European Journal of Surgical Oncology, 2021, 47, 1145-1151.	1.0	5
630	Confocal microscopy, dermoscopy, and histopathology features of atypical intraepidermal melanocytic proliferations associated with evolution to melanoma inAsitu. International Journal of Dermatology, 2021, 61, 167.	1.0	5

#	Article	IF	CITATIONS
631	Pembrolizumab versus placebo as adjuvant therapy in resected high-risk stage II melanoma: Phase 3 KEYNOTE-716 study Journal of Clinical Oncology, 2019, 37, TPS9596-TPS9596.	1.6	5
632	Management of pigmented skin lesions in childhood and adolescence. Australian Journal of General Practice, 2019, 48, 539-544.	0.8	5
633	Management of pigmented skin lesions during pregnancy. Australian Journal of General Practice, 2019, 48, 621-624.	0.8	5
634	L1CAM and laminin vascular network: Association with the high-risk replacement histopathologic growth pattern in uveal melanoma liver metastases. Laboratory Investigation, 0, , .	3.7	5
635	Cutaneous melanoma. Lancet, The, 2005, 365, 2003.	13.7	4
636	Cutaneous metastasis of epithelioid haemangioendothelioma. Pathology, 2009, 41, 585-587.	0.6	4
637	Tumor-infiltrating lymphocytes and mitotic index in metastatic melanoma as predictors of patient survival. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, E46; author reply E47.	7.1	4
638	Follicular dendritic cell sarcoma of the lung: a report of two cases highlighting its pathological features and diagnostic pitfalls. Pathology, 2011, 43, 67-70.	0.6	4
639	Synergistic effects of MAPK and immune checkpoint inhibitors in melanoma: what is the best combination strategy?. Melanoma Management, 2015, 2, 15-19.	0.5	4
640	Advances in melanoma: revolutionary progress delivering improved patient management and outcomes. Pathology, 2016, 48, 105-107.	0.6	4
641	Staging of Cutaneous Melanoma. JAMA Network Open, 2018, 1, e180086.	5.9	4
642	Whole brain radiotherapy (WBRT) after local treatment of brain metastases in melanoma patients: Statistical Analysis Plan. Trials, 2019, 20, 477.	1.6	4
643	Isolated Imunohistochemistry-positive Cells Without Morphologic Characteristics of Melanoma Should Not Result in Designation as a Positive Sentinel Lymph Node According to the AJCC 8th Edition Staging System. American Journal of Surgical Pathology, 2019, 43, 1442-1444.	3.7	4
644	Prognosis, Staging, and Reporting of Melanomas. , 2019, , 386-396.		4
645	A practical guide on the use of imiquimod cream to treat lentigo maligna. Australasian Journal of Dermatology, 2021, 62, 478-485.	0.7	4
646	LBA39 Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage IIIB-D melanoma patients (pts) stratified according to the interferon-gamma signature (IFN-γ sign): The DONIMI study. Annals of Oncology, 2021, 32, S1315.	1.2	4
647	Clinico-pathologic correlates of BRAF mutation status in 207 consecutive patients with metastatic melanoma Journal of Clinical Oncology, 2010, 28, 8548-8548.	1.6	4
648	Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo) Journal of Clinical Oncology, 2017, 35, TPS9600-TPS9600.	1.6	4

#	Article	IF	CITATIONS
649	Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomes. European Journal of Cancer, 2022, 167, 123-132.	2.8	4
650	Evaluation of the Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International, Multicenter Study. Annals of Surgical Oncology, 2022, 29, 5937-5945.	1.5	4
651	Test and teach Number Ninety-Four: Part 1. Pathology, 1999, 31, 217-218.	0.6	3
652	An unusual pleural spindle cell tumour Part 1. Pathology, 2002, 34, 370-374.	0.6	3
653	Asymptomatic linear pigmentation of the skin. International Journal of Dermatology, 2013, 52, 935-937.	1.0	3
654	Reply to M. Perier-Muzet et al. Journal of Clinical Oncology, 2014, 32, 3203-3204.	1.6	3
655	Diffuse melanosis cutis in the setting of BRAFV600Emetastatic melanoma. International Journal of Dermatology, 2014, 53, 1409-1411.	1.0	3
656	Multiparameter analysis of naevi and primary melanomas identifies a subset of naevi with elevated markers of transformation. Pigment Cell and Melanoma Research, 2016, 29, 444-452.	3.3	3
657	Pigmented Paget's disease of the nipple mistaken for melanoma in situ : a diagnostic pitfall for the unwary. Pathology, 2018, 50, 364-367.	0.6	3
658	Impact of genomics on the surgical management of melanoma. British Journal of Surgery, 2018, 105, e31-e47.	0.3	3
659	Inguinal and Ilio-inguinal Lymphadenectomy in Management of Palpable Melanoma Lymph Node Metastasis: A Long-Term Prospective Evaluation of Morbidity and Quality of Life. Annals of Surgical Oncology, 2019, 26, 4663-4672.	1.5	3
660	Knowledge and attitudes of Australian dermatologists towards sentinel lymph node biopsy for melanoma: a mixed methods study. Australasian Journal of Dermatology, 2021, 62, 168-176.	0.7	3
661	Estimating the potential impact of interventions to reduce overâ€calling and underâ€calling of melanoma. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1519-1527.	2.4	3
662	Lentigo maligna: defining margins and predictors of recurrence utilizing clinical, dermoscopic, confocal microscopy and histopathology features. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1811-1820.	2.4	3
663	Letter to the Editor. International Journal of Gynecological Cancer, 2003, 13, 98-100.	2.5	3
664	Phase 3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) following local treatment of 1-3 melanoma brain metastases (MBMs) Journal of Clinical Oncology, 2019, 37, 9500-9500.	1.6	3
665	Comprehensive molecular profiling of metastatic melanoma to predict response to monotherapy and combination immunotherapy Journal of Clinical Oncology, 2019, 37, 9511-9511.	1.6	3
666	Australian general practitioners' attitudes and knowledge of sentinel lymph node biopsy in melanoma management. Australian Journal of General Practice, 2020, 49, 355-362.	0.8	3

#	Article	IF	CITATIONS
667	SPINAL CHLOROMA PRESENTING WITH TRIPLEGIA IN AN ALEUKAEMIC PATIENT. Pathology, 2001, 33, 386-389.	0.6	3
668	Germline variants are associated with increased primary melanoma tumor thickness at diagnosis. Human Molecular Genetics, 2021, 29, 3578-3587.	2.9	3
669	Successful treatment of eruptive keratoacanthomas with actitretin for patients on checkpoint inhibitor immunotherapy. Journal of the European Academy of Dermatology and Venereology, 2022, 36,	2.4	3
670	The progressive relationship between increasing Breslow thickness and decreasing survival is lost in patients with ultrathick melanomas (≥15Âmm in thickness). Journal of the American Academy of Dermatology, 2022, 87, 298-305.	1.2	3
671	BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. Pathology, 2022, 54, 6-19.	0.6	3
672	Effect of the time interval between melanoma diagnosis and sentinel node biopsy on the size of metastatic tumour deposits in node-positive patients. European Journal of Cancer, 2022, 167, 133-141.	2.8	3
673	Sentinel lymph node biopsy rates in Victoria, 2018 and 2019. Medical Journal of Australia, 2022, 217, 208-209.	1.7	3
674	Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma. Pathology, 2022, 54, 533-540.	0.6	3
675	Comprehensive Clinical, Histopathologic, and Molecular Analysis and Long-term Follow-up of Patients With Nodal Blue Nevi. American Journal of Surgical Pathology, 2022, 46, 1048-1059.	3.7	3
676	Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge—December 1st–2nd, 2021. Journal of Translational Medicine, 2022, 20, .	4.4	3
677	Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases. Annals of Surgical Oncology, 2022, 29, 7019-7028.	1.5	3
678	Cross-Platform Omics Prediction procedure: a statistical machine learning framework for wider implementation of precision medicine. Npj Digital Medicine, 2022, 5, .	10.9	3
679	Test and Teach Number Ninety Six: Part 1. Pathology, 1999, 31, 372.	0.6	2
680	Cutaneous melanoma. Lancet, The, 2005, 365, 2004-2005.	13.7	2
681	Primary Melanoma of the Lung. American Surgeon, 2007, 73, 937-938.	0.8	2
682	Cutaneous Metastases. , 2010, , 637-650.		2
683	Retroperitoneal Inflammatory Liposarcoma in a Patient with Non-Hodgkin Lymphoma: A Report Highlighting Diagnostic Pitfalls. Pathology Research International, 2010, 2010, 1-4.	1.4	2
684	Completion lymph node dissection in melanoma patients with positive sentinel lymph nodes. European Journal of Surgical Oncology, 2013, 39, 1164-1165.	1.0	2

#	Article	IF	CITATIONS
685	Premalignancy: The lull before the storm. Pathology, 2013, 45, 207-208.	0.6	2
686	Multiple primary cutaneous melanomas: recent studies highlight features associated with more indolent behaviour. Pathology, 2013, 45, 1-3.	0.6	2
687	Prominent angiotropism in a small atypical spitzoid dysplastic melanocytic naevus: what is its significance?. Pathology, 2013, 45, 701-703.	0.6	2
688	Atypical naevus spilus: detection byin vivoconfocal microscopy. Clinical and Experimental Dermatology, 2014, 39, 616-619.	1.3	2
689	Authors' response to a reply to â€~A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients'. British Journal of Dermatology, 2017, 176, 552-553.	1.5	2
690	L3â€Update of the OpACIN and OpACIN-neo trials: 36-months and 24-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients. , 2020, 8, A2.1-A2.		2
691	Predicting Sentinel Node Status in Patients With Melanoma: Does Gene Expression Profiling Improve Accuracy?. JCO Precision Oncology, 2020, 4, 990-991.	3.0	2
692	Staging for Melanoma - Toward a New Paradigm?. Journal of the National Cancer Institute, 2020, 112, 873-874.	6.3	2
693	Publication metrics: it really is all about the numbers. Pathology, 2021, 53, 561-563.	0.6	2
694	Neoadjuvant immunotherapy in melanoma - the new frontier. Clinical Cancer Research, 2021, 27, clincanres.1236.2021.	7.0	2
695	Cutaneous clear cell sarcoma with an epidermal component mimicking melanoma. Pathology, 2022, 54, 369-371.	0.6	2
696	Residual melanoma in wide local excision specimens after â€~complete' excision of primary cutaneous in situ and invasive melanomas. Pathology, 2022, 54, 71-78.	0.6	2
697	Alcoholism and dementia. , 2004, , 427-441.		2
698	Abstract 2968: Exome sequencing of desmoplastic melanoma reveals recurrent NFKBIE promoter mutations and diverse MAPK/PI3K pathway activating mutations. Cancer Research, 2015, 75, 2968-2968.	0.9	2
699	Abstract 975: Liver metastases (mets) induce systemic immunosuppression and immunotherapy resistance in metastatic melanoma. , 2019, , .		2
700	Distinct gene expression, mutational profile and clinical outcomes of V600E and V600K/R BRAF-mutant metastatic melanoma (MM) Journal of Clinical Oncology, 2017, 35, 9541-9541.	1.6	2
701	BRAF inhibitor acquired resistance: A multicenter meta-analysis of the spectrum and clinical implications of resistance mechanisms Journal of Clinical Oncology, 2015, 33, 9008-9008.	1.6	2
702	Circulating tumor DNA (ctDNA) in metastatic melanoma (MM) patients (pts) with brain metastases (mets) Journal of Clinical Oncology, 2019, 37, 9581-9581.	1.6	2

#	Article	IF	CITATIONS
703	Clinical models to predict response and survival in metastatic melanoma (MM) patients (pts) treated with anti-PD-1 alone (PD1) or combined with ipilimumab (IPI+PD1) Journal of Clinical Oncology, 2019, 37, 9542-9542.	1.6	2
704	A phase II study of neoadjuvant pembrolizumab and lenvatinib for resectable stage III melanoma: The neopele study Journal of Clinical Oncology, 2020, 38, TPS10088-TPS10088.	1.6	2
705	Melanoma Prognosis and Staging. , 2020, , 271-297.		2
706	Abstract 2822: Low intestinal microbial diversity is associated with severe immune-related adverse events and lack of response to neoadjuvant combination antiPD1, anti-CTLA4 immunotherapy. , 2019, , .		2
707	Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA. Frontiers in Oncology, 2022, 12, 820510.	2.8	2
708	Development of melanoma clinical quality indicators for the Australian melanoma clinical outcomes registry (<scp>MelCOR</scp>): A modified Delphi study. Australasian Journal of Dermatology, 2022, , .	0.7	2
709	The Association Between Excision Margins and Local Recurrence in 1407 Patients with Primary In Situ Melanomas. JAAD International, 2022, , .	2.2	2
710	Cytoplasmic expression of nm23 predicts the potential for cerebral metastasis in patients with primary cutaneous melanoma. Melanoma Research, 2004, 14, 239.	1.2	1
711	Can Histologic Parameters of Melanoma Metastases in Sentinel Lymph Nodes Reliably Select Patients Who Can Be Safely Spared Completion Lymph Node Dissection?. Annals of Surgery, 2010, 251, 1188-1189.	4.2	1
712	Punch biopsy of melanoma causing tumour cell implantation: Another peril of utilising partial biopsies for melanocytic tumours. Australasian Journal of Dermatology, 2015, 56, 227-231.	0.7	1
713	Angiomatoid Spitz naevus: novel observations and clues to diagnosis of a rare variant. Pathology, 2016, 48, 739-742.	0.6	1
714	Reply to comment on: Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (<Â0.1Âmm) Sentinel Lymph Node Metastases. Annals of Surgical Oncology, 2017, 24, 660-660.	1.5	1
715	Advantages of whole-genome sequencing for identification of tumor etiology and clinically actionable genomic aberrations: lessons from the Australian Melanoma Genome Project. Melanoma Management, 2017, 4, 147-149.	0.5	1
716	The Importance of Population-Based Estimates of Melanocytic Pathology. JAMA Dermatology, 2018, 154, 15.	4.1	1
717	ASO Author Reflections: Long-Term Survival of Patients with Thin (T1) Cutaneous Melanomas. Annals of Surgical Oncology, 2018, 25, 918-919.	1.5	1
718	History of Melanoma. , 2018, , 1-13.		1
719	Diagnosing melanoma: the method matters. Medical Journal of Australia, 2019, 211, 209-210.	1.7	1
720	Novel Immune Targets in Melanoma—Response. Clinical Cancer Research, 2019, 25, 5424-5425.	7.0	1

#	Article	IF	CITATIONS
721	Comment on "Prognostic value of sentinel lymph node biopsy according to Breslow thickness for cutaneous melanoma― Journal of the American Academy of Dermatology, 2019, 80, e21-e22.	1.2	1
722	bcCST—an interactive bias-correction method to identify over-represented gene-sets in boutique arrays. Bioinformatics, 2019, 35, 1350-1357.	4.1	1
723	Metastatic Melanoma. , 2019, , 314-329.		1
724	Sentinel lymph node biopsy remains the most accurate method of obtaining staging and prognostic information for patients with primary cutaneous melanomas. Australasian Journal of Dermatology, 2019, 60, 75-76.	0.7	1
725	P01.15â€Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in macroscopic stage III melanoma patients stratified according to interferon-gamma (IFN-gamma) signature – the DONIMI study. , 2020, , .		1
726	Phenotypic Differences in Thyroid Immune Related Adverse Events Following Treatment With Immune Checkpoint Inhibitors. Journal of the Endocrine Society, 2021, 5, A876-A877.	0.2	1
727	Mucosal Melanoma. Surgical Pathology Clinics, 2021, 14, 293-307.	1.7	1
728	Abstract 2761: CODEX highly multiplex image mapping to CITEseq datasets reveal the spatial dynamics of the TME during the development of acquired resistant in immunotherapy treated melanoma. , 2021, , .		1
729	Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies. European Journal of Cancer, 2021, 153, 8-15.	2.8	1
730	ASO Visual Abstract: Survival Outcomes of SalvageÂMetastasectomyÂafter Failure ofÂModern-EraÂSystemic TherapyÂfor Melanoma. Annals of Surgical Oncology, 2021, 28, 597-598.	1.5	1
731	Classification and Histopathology of Melanoma. , 2020, , 317-379.		1
732	Abstract 3876: TRIM16 is a prognostic marker for patients with lymph node metastatic melanoma , 2013, , .		1
733	Phase III KEYNOTE-716 study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma Journal of Clinical Oncology, 2019, 37, TPS145-TPS145.	1.6	1
734	Abstract 3271: Different pathologic response rates between Australia and Europe in macroscopic stage III melanoma patients upon neoadjuvant ipilimumab plus nivolumab in the phase II OpACIN-neo trial. Cancer Research, 2020, 80, 3271-3271.	0.9	1
735	Abstract 913: Defining melanoma patients unresponsive to single agent anti-PD-1 therapy but responsive to combination anti-PD-1 + anti-CTLA-4 therapy. Cancer Research, 2020, 80, 913-913.	0.9	1
736	Pathology: the next chapter. Pathology, 2022, 54, 4-5.	0.6	1
737	Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma. Australasian Journal of Dermatology, 2022, 63,	0.7	1
738	Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre. Pathology, 2022, , .	0.6	1

#	Article	IF	CITATIONS
739	Reflectance confocal microscopy – a nonâ€invasive tool for monitoring systemic treatment response in stage III unresectable primary scalp melanoma. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	1
740	Multiple eruptive squamoproliferative lesions during antiâ€PD1 immunotherapy for metastatic melanoma: Pathogenesis, immunohistochemical analysis and treatment. Dermatologic Therapy, 2022, , e15472.	1.7	1
741	Neoadjuvant dabrafenib and trametinib (D+T) for stage III melanoma: Long-term results from the NeoCombi trial Journal of Clinical Oncology, 2022, 40, 9580-9580.	1.6	1
742	A subcutaneous nodule: another variant of a pseudotumour? Part 1. Pathology, 2002, 34, 466-470.	0.6	0
743	Clinical and histologic features of level 2 cutaneous malignant melanoma associated with metastasis. Cancer, 2002, 95, 671-672.	4.1	0
744	Challenging and Unusual Cases. Journal of Clinical Oncology, 2003, 21, 1420-1421.	1.6	0
745	Re: NM patients and SN. Journal of the Royal College of Surgeons of Edinburgh, 2007, 5, 320.	1.8	0
746	Correct identification of a sentinel node postselective lymphadenectomy using antimony levels. Melanoma Research, 2008, 18, 365-366.	1.2	0
747	Reply to I. Satzger et al. Journal of Clinical Oncology, 2011, 29, e316-e317.	1.6	0
748	A light shines on melanoma metastagenesis. Pigment Cell and Melanoma Research, 2014, 27, 696-697.	3.3	0
749	(S029) Development of an Immune-Associated Molecular Signature Predicting Melanoma Survival. International Journal of Radiation Oncology Biology Physics, 2017, 98, E9.	0.8	0
750	A 14â€Protein Signature for Rapid Identification of Poor Prognosis Stage III Metastatic Melanoma. Proteomics - Clinical Applications, 2018, 12, 1700094.	1.6	0
751	Desmoplastic Melanoma. , 2019, , 469-481.		0
752	Phase 3 International Trial of Adjuvant Whole Brain Radiotherapy (WBRT) or Observation (OBS) Following Local Treatment of 1-3 Melanoma Brain Metastases (MBMs). International Journal of Radiation Oncology Biology Physics, 2019, 105, S139-S140.	0.8	0
753	Pathological re-classification of basal cell carcinomas from the ontrac skin cancer chemoprevention study and the new who skin blue book. Pathology, 2019, 51, S8.	0.6	0
754	Characterisation of peripheral blood mononuclear cells in patients with combination ipilimumab and nivolumab therapy-related colitis. European Journal of Cancer, 2019, 110, S21-S22.	2.8	0
755	Quality of Life Following Surgical Excision of Early-Stage Melanoma of the Head and Neck. JAMA Dermatology, 2019, 155, 502.	4.1	0
756	IMMU-04. TEMPORAL AND SPATIAL MODULATION OF THE IMMUNE RESPONSE OF THE MURINE GL261 GLIOMA TUMOUR MICROENVIRONMENT. Neuro-Oncology, 2019, 21, vi119-vi119.	1.2	0

#	Article	IF	CITATIONS
757	Combined Melanocytic Nevi. , 2019, , 112-123.		0
758	Acral and Subungual Melanoma. , 2019, , 168-180.		0
759	Response to Letter to the Editor: "Checkpoint Inhibitor-Associated Autoimmune Diabetes is Distinct From Type 1 Diabetes― Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2317-e2318.	3.6	0
760	Analysis of clinical and molecular profiles of patients with innate resistance to ANTI-PD-1 +/- ANTI-CTLA-4 immunotherapy in metastatic melanoma. Pathology, 2021, 53, S60.	0.6	0
761	Abstract 2609: Hypoxia-mediated downregulation of GCNT2/I-antigen in metastatic melanoma accelerates disease progression and mortality. , 2021, , .		0
762	Abstract 2762: Spatial distribution and immune cell infiltration at different sites of melanoma metastases (mets). , 2021, , .		0
763	ASO Author Reflections: Surgical Resection May Improve the Outcome for Patients with Residual Metastatic Melanoma When Modern Systemic Therapies Have Not Achieved Complete Disease Control. Annals of Surgical Oncology, 2021, 28, 6124-6125.	1.5	0
764	Characterizing the Clinical Implications of Histologic Regression in Melanoma Requires Clear Diagnostic Criteria That Are Consistently Applied—Reply. JAMA Dermatology, 2021, 157, 1006.	4.1	0
765	1092TiP Investigational (Inv) agents with or without pembrolizumab (pembro) or pembro alone in melanoma (mel): KEYMAKER-U02. Annals of Oncology, 2021, 32, S903.	1.2	0
766	Road to Metastasis: The TWEAK Pathway as a Discriminant between Metastasizing and Non-Metastasizing Thick Melanomas. International Journal of Molecular Sciences, 2021, 22, 10568.	4.1	0
767	1500P Health-related quality of life in melanoma patients treated with neoadjuvant nivolumab and domatinostat: Preliminary results. Annals of Oncology, 2021, 32, S1100-S1101.	1.2	0
768	Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. An EORTC Melanoma group study. Journal of Clinical Oncology, 2007, 25, 8509-8509.	1.6	0
769	Abstract B8: Galectin-1 expressed in human melanoma is bound to cancer stem cells: A driver for metastatic progression and target for antimetastatic cancer therapy. , 2013, , .		0
770	Metastatic Melanoma. , 2014, , 529-567.		0
771	Correlation between pre-existing MEK1P124 mutations and clinical and in vitro response to BRAF inhibitors in metastatic melanoma Journal of Clinical Oncology, 2014, 32, 9004-9004.	1.6	0
772	Pharmacokinetic and pharmacodynamic analysis of preoperative therapy with dabrafenib alone and in combination with trametinib in patients with BRAF mutation–positive melanoma with metastases to the brain (BRV116521) Journal of Clinical Oncology, 2014, 32, TPS9112-TPS9112.	1.6	0
773	Whole exome paraffin sequencing (WEPS) of same-patient (pt) primary, extracranial, and melanoma brain metastases (PEB) to identify new driver and clonal evolution genetic events Journal of Clinical Oncology, 2015, 33, e20033-e20033.	1.6	0
774	PD-L1 expression, immune cell correlates, and PD-1+ lymphocytes in sentinel lymph node positive melanoma patients: Implications for adjuvant PD-1 clinical trials Journal of Clinical Oncology, 2015, 33, e20011-e20011.	1.6	0

#	Article	IF	CITATIONS
775	Abstract 56: Receptor-Interacting protein kinase 1 functions as an oncogenic regulator in human melanoma. , 2015, , .		0
776	Abstract 5025: Immune expression profiling of MAPK inhibitor resistant tumors based upon mechanisms of resistance. , 2015, , .		0
777	Abstract 4718: Inositol polyphosphate 4-phosphatase II activates PI3K/SGK3 signaling to promote proliferation of human melanoma cells. , 2015, , .		Ο
778	Abstract A024: Protein microarrays for the immunological profiling of melanoma. , 2016, , .		0
779	Abstract 2650: In depth immune profiling of the response of melanoma to MAPK inhibition. , 2016, , .		Ο
780	Differences in immune profiles of metastatic melanoma patients treated with anti-CTLA-4 and anti-PD-1 combined immunotherapy Journal of Clinical Oncology, 2017, 35, 51-51.	1.6	0
781	Analysis of mutational burden and adaptive immune response in desmoplastic melanomas treated with PD-1/L1 inhibitors Journal of Clinical Oncology, 2017, 35, 9558-9558.	1.6	Ο
782	Abstract 2206: Proteome phenotype of stage III metastatic melanoma and response to MEK inhibition. , 2017, , .		0
783	Abstract LB-031: Deciphering distinct roles of RASA2 in melanomagenesis. , 2017, , .		Ο
784	Abstract 5528: The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene. , 2017, , .		0
785	Transcriptomic and immunophenotypic profiles of melanoma tissue from patients (pts) treated with anti-PD-1 +/- ipilimumab to define mechanisms of response and resistance Journal of Clinical Oncology, 2018, 36, 9518-9518.	1.6	Ο
786	Abstract LB-121: Exploring the germ-line contribution to exceptional response to PD-1/PD-L1 inhibition in patients with metastatic non-small-cell lung cancer by whole genome sequencing. , 2018, , .		0
787	Abstract LB-146: T cell receptor immunosequencing improves prediction of melanoma recurrence. , 2018, , .		Ο
788	Abstract 2420: Skp2-mediated stabilization of MTH1 promotes survival of melanoma cells upon oxidative stress. , 2018, , .		0
789	Classification and Histopathology of Melanoma. , 2019, , 1-64.		Ο
790	Desmoplastic Melanoma. , 2019, , 1-13.		0
791	Melanoma Prognosis and Staging. , 2019, , 1-27.		0
792	Case report of a challenging mediumâ€sized congenital melanocytic nevus (CMN): Highlighting a role for reflectance confocal microscopy (RCM) for evaluating changing CMN in children. Pediatric Dermatology, 2021, , .	0.9	0

#	Article	IF	CITATIONS
793	426â€MK-3475-U02: Phase 1/2 study of investigational agents with or without pembrolizumab versus pembrolizumab monotherapy in melanoma. , 2020, , .		0
794	Competing risks analysis with missing cause-of-failure—penalized likelihood estimation of cause-specific Cox models. Statistical Methods in Medical Research, 2022, , 096228022110702.	1.5	0
795	Re: Reply to letter to the editor re: â€~practical guide on the use of imiquimod cream to treat lentigo maligna'. Australasian Journal of Dermatology, 2022, , .	0.7	Ο
796	Effect of the <scp>SunSafe</scp> Training Program on the attitudes, knowledge, and behaviour of Australian high school students towards sun safety: a prospective study. Clinical and Experimental Dermatology, 2022, , .	1.3	0
797	Abstract 3246: Dynamics of T-cell checkpoint receptor profiles during melanoma progression. , 2019, , .		Ο
798	Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spread. Melanoma Research, 2022, Publish Ahead of Print, .	1.2	0
799	A tool to predict survival outcomes and guide adjuvant immunotherapy recommendations for patients with stage II melanoma Journal of Clinical Oncology, 2022, 40, e21556-e21556.	1.6	0
800	VEGF inhibitors (VEGFi) activity in liver metastases (mets) regardless of primary cancer type: Meta-analysis and systematic review Journal of Clinical Oncology, 2022, 40, 3024-3024.	1.6	0
801	A biomarker-guided Bayesian response-adaptive phase II trial for metastatic melanoma: The Personalized Immunotherapy Platform (PIP) trial design Journal of Clinical Oncology, 2022, 40, TPS9599-TPS9599.	1.6	0